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Skeletal muscle wasting occurs in several physio-pathological conditions and represents one of the 
main overlapping features between the physiological age-related sarcopenia and cachexia, which 
often associates with an underlying disease, such as cancer.  
The physiopathology of both sarcopenia and cancer cachexia is complex and multifactorial, however 
hormonal network dysregulation co-occurs in both these muscle wasting-inducing conditions, where 
it might participate to prompt skeletal muscle decline. Vitamin D (VD) and Ghrelin came up among 
the dysregulated hormones in sarcopenia as well as in cancer cachexia.   
Vitamin D (VD) is a pleiotropic hormone that, besides its well-known role in regulation of calcium 
and phosphate homeostasis, impacts on skeletal muscle homeostasis as well, and VD deficiency has 
been correlated with decrease in muscle mass, function, and performance in various conditions, 
including sarcopenia. Notably, in elderly subjects, VD supplementation was able to restore muscle 
strength and prevent muscle mass loss. Since VD deficiency is highly prevalent also among advanced 
cancer patients with cachexia, the encouraging results of VD supplementation on frail elderly subjects 
led to the hypothesis that VD supplementation could be used as an anti-cachexia treatment. However, 
VD administration was ineffective to counteract cancer cachexia associated-muscle wasting both in 
patients and in animal models.  
We show how variously hydroxylated VD metabolites and the differential regulation of VD 
hydroxylases may trigger contrasting effects on skeletal muscle in vitro, thus explaining the opposite 
outcome of VD supplementation in vivo and paving the way to new drugs with restricted 
hydroxylability to overcome the limitations of VD supplementation in some pathological conditions. 
Ghrelin is a gastric hormone peptide circulating in both acylated (AG) and unacylated (UnAG) forms. 
AG is the endogenous ligand of the growth hormone secretagogue receptor (GHSR-1a), and it is 
involved in metabolic regulation and energetic balance through induction of appetite, food intake, 
and adiposity. UnAG does not induce GH release and has no direct effects on food intake, but it shares 
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with AG several biological activities, in particular both AG and UnAG have direct biological 
activities in vitro on skeletal muscle.  
Low ghrelin circulating levels have been observed in elderly subjects, and this condition could 
participate in the establishment of sarcopenia by facilitating the progression of muscle atrophy and 
limiting skeletal muscle regeneration capability.  
Administration of AG analogues has been explored in several conditions characterized by muscle 
wasting, including cancer cachexia and aging. However, in sarcopenia, conversely to the beneficial 
effects observed in cancer cachexia, the administration of AG display scarce effect on skeletal muscle 
accompanied by an increase in adiposity that might worsen age-related insulin resistance and 
metabolic dysfunction.  
We show that not only lifelong overexpression of UnAG in mice, but also the deletion of ghrelin gene 
attenuated the age-associated muscle atrophy and functionality decline, as well as systemic 
inflammation, prompting the design of UnAG mimetics which could be more useful than AG analogs 
for the treatment of sarcopenia.  
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Skeletal muscle homeostasis 
Skeletal muscle, which account for about half of mammals body weight, has evolved to allow 
movement in animals, indeed it has primarily characterized by its mechanical activity required for 
posture, movement, and breathing (Janessen et al. 2000).    
The functional unit of skeletal muscle is a long cylindrical multinucleated myofibers composed by 
myofibrils made up of thousands of sarcomeres, containing the actin and myosin filaments that 
interact to produce contraction. Multinucleated myofibers originate from the fusion of many 
myoblasts during embryonic and foetal development, and post-natal growth (Mintz and Baker, 1967). 
Since skeletal muscle consists of the largest pool of proteins in the whole organism, this specific 
tissue is highly sensitive under conditions that alter protein balance. Indeed, skeletal muscle mass 
reflects protein turnover, depending on the balance between pathways favouring protein synthesis or 
breakdown. The best characterized anabolic pathway involves activation of the serine/threonine 
kinase Akt which results in downstream amplification of mammalian target of rapamycin (mTOR) 
that induces protein synthesis (Bodine et al, 2001). A variety of stimuli activate this pathway, such as 
insulin-like growth factor-1 (IGF-1), branched chain amino acids, exercise, and testosterone. On the 
other side, the ubiquitin proteasome pathway and autophagy-lysosome system are the major pathways 
driving muscle protein breakdown. These degradation systems are controlled by the transcription 
factors forkhead O (Fox-O) and nuclear factor (NF)-κB (Fig. 1). Among the ubiquitin-proteasome 
proteolytic system two genes, atrogin-1/MAFbx and MuRF1, have been observed dramatically 
upregulated prior the onset of muscle loss in multiple experimental models (Bodine et al., 2001; 
Taillandier et al., 2019). Both these genes encode proteins that are referred to as E3 ubiquitin ligases, 
which are responsible for substrate specificity of ubiquitin conjugation. The autophagy-lysosome 
system activation determines the formation of double-membrane vesicles named autophagosomes, 
which are able to engulf a portion of the cytosol and fuse with lysosomes, where their content is 
completely degraded by lytic enzymes. Although basal autophagy is crucial for the maintenance of 
muscle homeostasis, the overactivation of autophagic flux leads to muscle atrophy (Bonaldo and 
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Sandri, 2013). LC3, Gabarap and CathepsinL are autophagy-related genes upregulated in a variety of 
muscle wasting-associated conditions (Lecker et al., 2004; Sacheck et al., 2007).  
Myostatin, member of the transforming growth factor β (TGFβ) family, is another negative regulator 
of muscle mass, downregulating the Akt/mTOR pathway and by decreasing the number of satellite 













Figure 1. Overview of IGF-1/Akt signalling pathway. Scheme representing how IGF1/Akt pathway induces muscle 
growth by acting on mTOR and FoxO (Schiaffino and Mammucari, 2011).  
 
The alteration of the balance between synthetic and degradation pathways results in muscle atrophy. 
Skeletal muscle impairment occurs in several conditions and represents one of the main overlapping 
features between cachexia, where is due to an underlying disease, and the physiologic sarcopenia 












Figure 2. Representation of the main feature of both cachexia and sarcopenia (Adapted by Argilés et la., 2015) 
 
Sarcopenia 
Sarcopenia is a multifactorial age-related process defined as a progressive and generalized loss of 
muscle mass and strength with the risk of adverse outcome (Cruz-Jentoft AJ et al., 2010). Starting 
from the fifth decade of life, this progressive age-related muscle wasting affects up to 33% of 
individuals and correlates with increased risk of physical frailty, functional impairment, poor health-
related quality of life, disability and premature death (Visser M et al., 2011; Van Kan GA 2009; 
Bunout D et al., 2011  ̧Cruz-Jentoft AJ et al., 2014).  
Cellular, hormonal, metabolic, and molecular mechanisms trigger the development of sarcopenia, 
including impaired insulin signaling, imbalance anabolic and catabolic energy metabolism, 
upregulation of cytokine expression, immune dysfunction, systemic inflammation, and increased 
oxidative stress (Sayer et al., 2010). Aging disturbs the homoeostasis of skeletal muscle, causing an 
imbalance between muscle protein anabolic and catabolic pathways, that in turn lead to muscle 
wasting. Cellular changes in sarcopenic muscle include a reduction in the size and number of 
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myofibers, which particularly affects type II fibers, partly due to and fewer type II fiber satellite cells. 
Additionally, a transition of muscle fibers from type II to type I occurs with age, together with fat 
infiltration (myosteatosis). Moreover, mitochondrial integrity in myocytes is altered and molecular 
changes, involving alterations to the IGF-1/Akt signaling pathway, ensue (Cruz-Jentoft and Sayer, 
2019). 
Even if the pathophysiology of sarcopenia is complex and multifactorial, among the causes triggering 
skeletal muscle decline could be included the alteration in several hormonal networks.  The endocrine 
system regulation is smashed up during aging, in fact hormones involved in inflammatory processes, 












Fig. 3. Representation of a general deregulation of trophic hormones that impact skeletal muscle and could 
contribute to the onset of sarcopenia. 11βHSD-1: 11β-hydroxysteroid dehydrogenase type 1. ACTH: 
adrenocorticotropin hormone. DHEA: Dehydroepiandrosterone. GH: growth hormone. IGF-1: insulin-like growth factor 





Actually, a variety of circulating hormones result deregulated during aging, and most of them display 
effects on both muscle growth and muscle function. However, albeit evidence suggesting the 
involvement of trophic hormones impairment in the establishment of sarcopenia, data about the 
efficacy of hormone replacement therapy in elderly sarcopenic subjects are still partial and unclear.  
 
Cachexia 
Cachexia is a life-threatening multifactorial syndrome often seen in progressive illnesses, such as 
cancer, chronic heart failure, chronic kidney disease, chronic obstructive pulmonary disease (COPD), 
and multiple sclerosis. Particularly in cancer, the prevalence of cachexia varies from 50% to 85% 
depending on the tumor type (Dodson et al., 2011). Cachexia is a marker of unfavorable prognosis, 
and it is directly responsible for at least 20% of cancer-related deaths (Vaughan et al., 2013).  
Cancer cachexia has been defined as a multifactorial syndrome characterized by an ongoing loss of 
skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional 
nutritional support and leads to progressive functional impairment. The pathophysiology is 
characterized by a negative protein and energy balance driven by a variable combination of reduced 
food intake and abnormal metabolism (Fearon et al., 2011). Cancer cachexia is characterized by 
systemic inflammation, negative protein and energy balance, progressive weight and skeletal muscle 
loss. Moreover, cachexia has a detrimental impact on cancer therapy, as cachectic patients are usually 
less tolerant to radio- and chemotherapy because of general weakness and discomfort (Fearon et al., 
2010).  
Several mechanisms participate in the establishment and development of cachexia, including 
anorexia, decreased physical activity, decreased secretion of host anabolic hormones, and an altered 
host metabolic response. (Mantovani and Madeddu, 2010). Systemic inflammation is considered a 
cancer cachexia hallmark, as pro-inflammatory cytokine activity increases during cancer progression 
Argilés et al., 2009; MacDonald et al., 2003). Numerous cytokines, including tumor necrosis factor-
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alpha (TNF-α), interleukin-1 (IL-1), IL-6, and interferon-gamma (IFN-γ), play a role in the etiology 
of cancer cachexia (Fearon et al., 2012; DoDson et al., 2011). Specifically, TNF-α and IL-6 induce 
myofibrillar breakdown by activation of the ubiquitin-proteasome pathway, via NF-κB-dependent 
and independent mechanisms (Ali and Garcia, 2014). Moreover, downregulation of IGF-1 anabolic 
pathway, androgens and satellite cell proliferation, and increases in catabolic processes such as 
apoptosis (Busquets et al., 2007), autophagy (Penna et al., 2013), mitochondrial dysfunction (Kang 
et al., 2013) and the myostatin pathway (Padrao et al., 2013) contribute to muscle mass and function 
loss in this setting.  
Although the underlying causes of cachexia are still largely unknown, the emerging thesis that cancer 
cachexia-associated muscle wasting could contribute to tumor growth and progression (Luo et al., 
2014) on one side, and the demonstration that prevention of skeletal muscle wasting in tumor-bearing 
animals is sufficient to markedly prolong their survival (Zhou et al., 2010) on the other hand, 
















Figure 4. Mechanisms involved in cancer cachexia. Tumor-derived catabolic factors such as proinflammatory 
cytokines act on target tissues to elicit excess catabolism. Alteration of the central nervous system results in reduced food 
intake. Proteolysis is induced in skeletal muscle through up-regulation of the ubiquitin-proteasome system and autophagy, 
and protein synthesis is reduced. Loss of adipose tissue results from increased lipolysis, decreased lipogenesis and 
adipogenesis and white adipose tissue browning. (Tsoli et al., 2013) 
 
 
As previously reported, alterations in several hormonal networks co-occur in skeletal muscle wasting 
and are regarded as possible causes triggering skeletal muscle decline. During my PhD internship, I 
particularly focused on vitamin D and ghrelin, analyzing the relationship between these hormones 




Vitamin D (VD) is a group of fat-soluble secosteroids that includes two compounds: vitamin D3 (also 
known as cholecalciferol, hereafter VD3) and vitamin D2 (ergocalciferol, hereafter VD2).  
VD2 originates from the UV irradiation of the yeast sterol ergosterol and is found naturally in sun-
exposed mushrooms, whereas VD3 come either from endogenous synthesis in the skin or from food, 
as oil-rich fish like salmon, mackerel, and herring. Since humans synthesize VD3 but not VD2, the 
first one is considered the most “natural” form.  Moreover, VD2 is chemically different from, and 
less physiologically active than, VD3 (Nair et al., 2012; Hymøller et al., 2016).  
In humans, VD3 synthesis begins with skin exposure to ultraviolet B radiation and the consequent 
photochemical conversion of the precursor, 7-dehydrocholesterol (pro-vitamin D), in pre-VD3. 
Through thermal isomerization, pre-VD3 is converted to VD3 (cholecalciferol) which reaches the 
liver where it is converted in 25-hydroxyvitamin D3 (25 VD) mainly by cytochrome P450 cyp2R1. 
Successively, 25 VD is transported to kidney where is converted in 1,25-dihydroxyvitamin D3 
(1,25VD) by cytochrome P450 cyp27b1. While 25-hydroxylation generally is not rate limiting, 1α-
hydroxylation step is strictly regulated. Lastly, cyp24a1 catalyzes the conversion of both 25 VD and 
1,25 VD into 24-hydroxylated products targeted for inactivation and excretion. 1,25 VD is considered 
the active form that, through the binding to Vitamin D receptor (VDR), exerts its biological activity 
















Figure 5. VD metabolism representation. (Adapted by Girgis et al., 2013). 
 
VD plays an essential role in regulating calcium and phosphate metabolism and maintaining a healthy 
mineralized skeleton. Thus, VD promotes intestinal calcium absorption and maintains adequate 
serum calcium and phosphate concentrations to enable bone mineralization. Moreover, VD is also 
needed for bone growth and remodeling driven by osteoblasts and osteoclasts. A longstanding VD 
deficiency has been associated with growth retardation and rickets in children, and osteoporosis or, 
in the most severe cases, osteomalacia in adults (Bischoff-Ferrari et al., 2009).  
Apart its consolidate role in bone metabolism, VD system regulates cell differentiation, cell cycle, 
and exerts pleiotropic effects on extra-skeletal target tissues, such as immune and cardiovascular 




















Figure 6. VD is a pleiotropic hormone. Representation of principal VD target tissues and actions (Casado et al., 2017). 
 
VD modulates B and T lymphocyte function (Tsoukas et al., 1984; Drozdenko et al., 2014 ), and VD 
deficiency has been associated with conditions such as multiple sclerosis, type 1 diabetes (T1D), 
rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, inflammatory bowel disease, 
hepatitis, asthma and respiratory infections (reviewed by Marino and Misra, 2019).  
Besides, 1,25(OH)2D has a direct action on myocardial cells, smooth muscle fibers, and vascular 
endothelial cells by stimulating the calcium ATPase activity, promoting the calcium transfer to the 
intracellular space (Wolden-Kirk et al., 2012). VD deficiency has been associated with inflammation 
and endothelial and platelet dysfunction, which favors the risk of cardiovascular complications 
(Kunadian et al., 2014). VDR is also expressed in pancreatic cells and VD affects glucose homeostasis 
as well, with a direct effect on the β-cell function and insulin secretion (Alvarez and Ashraf, 2010). 
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Several studies have suggested that low VD status contributes to insulin resistance (Teegarden and 
Donkin, 2009) and is associated with markers of impaired glucose metabolism, such as glycosylated 
hemoglobin (Kositsawat et al., 2010).  
VD metabolizing enzymes and VDR are expressed also in adipose tissue, then VD regulates 
adipogenesis, adipocyte apoptosis, affects energy metabolism by controlling the expression of 
uncoupling proteins, and the appetite suppressing leptin. Furthermore, VD reduces adipose tissue 
inflammation and VD deficiency is associated with obesity (Abbas, 2017).   
 
Vitamin D and skeletal muscle 
Among its extra-skeletal target tissue, VD impacts on skeletal muscle as well. The description of a 
reversible myopathy associated with VD deficiency leads to recognize a potential association between 
VD and muscle (Boland, 1986). The identification of the VD receptor (VDR) on muscle cells (Zanello 
et al., 1997; Bischoff et al., 2001) provided a solid evidence of the direct effect of VD on muscle 
tissue. Moreover, the expression in skeletal muscle of 1α‐hydroxylase, the enzyme responsible for 
the hydroxylation of 25 VD to 1,25 VD, gave another evidence of the direct action of VD on muscle 
(Srikuea et al., 2012).   
VD deficiency has been correlated with decrease in muscle mass, function, and performance in 
various pathologies, such as chronic kidney disease (Jean et al., 2017), inflammatory bowel diseases 
(Mager et al., 2018), COPD (Graumam et al., 2018), and myasthenia gravis (Kang et al., 2018), as 
well as in elderly subjects (Snijder et al., 2006; Suzuki et al., 2008).  
Despite VD clearly impacts on muscle homeostasis, the mechanisms through which it acts and its 
effects are still controversial. Some studies indicated that treatment of C2C12 myoblasts with 1,25 
VD resulted in increased VDR expression, inhibition of cell differentiation and proliferation, and 
down-regulation of myogenin (Srikuea et al., 2012; Girgis et al., 2014). In contrast, other studies 
reported that 1,25-(OH)2-VD stimulates myogenesis in satellite cells and C2C12 myocytes (Buitrago 
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et al. 2012; Braga et al., 2017). Others demonstrate that both 1,25-(OH)2-VD and 25-OH-VD 
stimulate VDR mRNA expression and reduce C2C12 cell proliferation without affecting myotube 
size or myogenin mRNA expression (van der Meijden et al., 2016). 
 
Vitamin D in sarcopenia 
25 VD circulating levels drop off with aging and VD deficiency is common amongst elderly subjects. 
This condition could be due to a decreased dietary intake, limited sunlight exposure, decreased 
capacity of human skin to produce VD3, reduced intestinal absorption, and impaired hydroxylation 
in the liver and kidneys (Janssen et al., 2002; Mosekilde, 2005). Likewise, an age-dependent decrease 
in VDR expression has been observed in skeletal muscle (Bischoff-Ferrari et al., 2004). Notably, a 
significant correlation was found between serum levels of VD metabolites and muscle strength and 
physical performance (Janssen et al., 2002). Randomized controlled trials and meta-analyses support 
the role of VD in improving age-related declines in muscle function as well (Wagatsuma et al., 2014; 
Caristia et al., 2019). Moreover, observational data have suggested the presence of a relationship 
between low 25 VD serum levels and impaired physical function in elderly populations (Bischoff-
Ferrari et al., 2004). Anyway, it has been reported that VD supplementation have beneficial effects 
to restore muscle strength, without affect muscle mass in the elderly, but preventing muscle loss 
(Mosekilde, 2005; Beaudart et al., 2014; Cangussu et al., 2015; Iolascon et al. 2017). The risk of falls 
and hip fractures increases in older people, owing to a loss of skeletal muscle mass and strength, and 
low vitamin D status plays a central role in the risk of falls in older people (Kim et al., 2011; 
Domingues-Faria et la., 2017). Actually, VD supplementation has been shown to reduce falls and 
fractures within elderly subjects affected by VD deficiency (Bischoff-Ferrari HA, 2012; Scott el al., 
2015).  
Nevertheless, the molecular mechanisms trough which VD acts in sarcopenia context remains to be 
fully elucidated.
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Vitamin D in cachexia 
Decreased circulating VD levels have been observed in 47% of oncologic patients (Dev et al, 2011), 
and reduction in mortality was reported in patients with colorectal cancer who presented adequate 
levels of vitamin D, suggesting the importance of maintaining vitamin D status (Mohr et al., 2015).  
Despite the well-established role of VD in muscle homeostasis, few studies have been performed on 
the efficacy of adequate VD levels in cachectic cancer patients. 
A phase II trial in which VD was supplemented to 6 patients with advanced prostate cancer showed 
an improvement of muscle strength (Van Veldhuizen et al., 2000). Moreover, data from 308 patients 
who underwent chemotherapy for breast cancer show higher disease-free survival in patients 
supplemented with vitamin D (Zeichner et al., 2015). However, a phase III trial with 953 patients was 
prematurely stopped after an interim analysis showed greater mortality in the supplemented versus 
placebo arm (Scher et al., 2011). The lack of effectiveness of VD supplementation in preventing 
cancer cachexia-associated muscle wasting was demonstrated also in tumor-bearing animals 
(Camperi et al., 2017). Nonetheless, another recent study showed that treatment with 1,25 prevented 
the changes in myoblasts induced by Lewis Lung carcinoma, suggesting that the treatment may be 
effective in counteracting cancer cachexia-associated muscle weakness (Ryan et al., 2018).  
The contrasting data about the effect of VD supplementation highlighted the urgency to elucidate the 
mechanisms by which VD system impact on skeletal muscle in cancer cachexia.  
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Introduction to the paper “Opposing effects of 25‐hydroxy‐ and 1α,25‐
dihydroxy‐vitamin D3 on pro‐cachectic cytokine‐and cancer 
conditioned medium-induced atrophy in C2C12 myotubes” 
 
Sustova H, De Feudis M, Reano S, Alves Teixeira M, Valle I, Zaggia I, Agosti E, Prodam F, 
Filigheddu N. 
Acta Physiol (Oxf). 2019 Jul;226(3):e13269. doi: 10.1111/apha.13269.
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Subjects affected by muscle wasting-associated conditions, as sarcopenia and cancer cachexia, often 
display VD deficiency (Snijder et al., 2006; Suzuki et al., 2008; Dev et al., 2011), which correlates 
with decrease in muscle function and performance and increase in disability, especially in elderly 
subjects. Since VD supplementation was able to restore muscle strength and prevent muscle mass 
loss in frail aged subjects, it has been hypothesized that VD supplementation could be used as an anti-
cachexia treatment. However, despite encouraging results on elderly, VD supplementation was 
ineffective against cancer cachexia-associated muscle wasting both in patients and in animal models 
(Scher et al., 2011; Camperi et al., 2017).  
In order to understand the underlying causes of contrasting effect of VD administration in sarcopenia 
and cancer cachexia, we explored the biological effects and mechanisms of different VD metabolites 
on C2C12 myotubes undergoing cancer cell conditioned medium- or cytokines-mediated atrophy as 
a model of in vitro cachexia-associated muscle wasting. 
Although 1,25 VD is considered the active form, we demonstrated that also the other VD metabolites 
can directly affect skeletal muscle derived cells. Interestingly, we showed that 25VD and 1,25VD 
have antithetical effects. 25 VD exerts a protective effect against cytokine-induced atrophy in vitro, 
while 1,25 VD induces atrophy, highly likely due to a differential modulation of 24-hydroxylase. 
Accordingly, we proved that 24,25 VD affects C2C12 myotube size as well. 
Altogether, our data show how variously hydroxylated VD metabolites and the differential regulation 
of VD hydroxylases may trigger contrasting effects in C2C12 myotubes, thus explaining the opposite 
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Abstract
Aim: Loss of skeletal muscle is one of the main features of cancer cachexia. Vitamin 
D (VD) deficiency is associated with impairment of muscle mass and performance 
and is highly prevalent in cachectic patients; therefore, VD supplementation has been 
proposed to counteract cancer cachexia‐associated muscle loss. However, in both 
cachectic cancer patients and tumour‐bearing animals, VD supplementation led to 
disappointing results, urging the need for a better understanding of VD activity on 
skeletal muscle.
Methods: Cancer‐associated muscle wasting was reproduced in vitro by treating 
C2C12 myotubes with cancer cell conditioned medium, a combination of TNF‐α and 
IFNγ or IL‐6 pro‐cachectic cytokines. The biological effects and mechanisms of ac-
tion of 1,25‐dihydroxy VD (1,25 VD) and its precursor 25‐hydroxy VD (25 VD) on 
myotubes were explored.
Results: We demonstrated that only 25 VD was able to protect from atrophy by ac-
tivating Akt signalling, inducing protein synthesis, and stimulating the autophagic 
flux, while 1,25 VD had an atrophic activity per se, increasing FoxO3 levels, induc-
ing the expression of atrogenes, and blocking the autophagic flux. Furthermore, we 
showed that the contrasting activities of these VD metabolites on C2C12 myotubes 
depend on a differential induction of VD‐24‐hydroxylase and transformation of VD 
metabolites in pro‐atrophic 24‐hydroxylated products, as silencing of VD‐24‐hy-
droxylase reduced the atrophic activity of 1,25 VD.
Conclusions: Altogether these data might explain the lack of efficacy of VD treat-
ment in vivo for the protection of muscle mass in cancer.
K E Y W O R D S
atrogenes, autophagy, cancer cachexia, Cyp24a1 24‐hydroxylase, Cyp27b1 1α‐hydroxylase, 
skeletal muscle atrophy
2 of 10 |   SUSTOVA eT Al.
1 |  INTRODUCTION
Cachexia is a life‐threatening multifactorial syndrome often 
seen in progressive illnesses, such as cancer, chronic heart 
failure, chronic kidney disease, chronic obstructive pulmo-
nary disease (COPD), and multiple sclerosis. Particularly 
in cancer, the prevalence of cachexia varies from 50% to 
85% depending on the tumour type.1 Cachexia is a marker 
of unfavourable prognosis, and it is directly responsible for 
at least 20% of cancer‐related deaths.2 Cancer cachexia is 
characterized by systemic inflammation, negative protein 
and energy balance, progressive weight and skeletal muscle 
loss. Moreover, cachexia has a detrimental impact on can-
cer therapy, as cachectic patients are usually less tolerant 
to radio‐ and chemotherapy because of general weakness 
and discomfort.3 To date, the underlying causes of cachexia 
are still largely unknown; but the emerging thesis that can-
cer cachexia‐associated muscle wasting could contribute 
to tumour growth and progression4 on one side, and the 
demonstration that prevention of skeletal muscle wasting 
in tumor‐bearing animals is sufficient to markedly prolong 
their survival5 on the other hand, prompted the search for 
suitable approaches to protect muscle wasting in cancer 
patients.
Vitamin D3 (cholecalciferol, VD hereafter for brevity), be-
sides its well‐known role in regulation of calcium and phos-
phate homeostasis, impacts on skeletal muscle homeostasis 
as well, and VD deficiency has been correlated with decrease 
in muscle mass, function, and performance in various pathol-
ogies, such as chronic kidney disease,6 inflammatory bowel 
diseases,7 COPD,8 and myasthenia gravis,9 as well as in el-
derly subjects.10,11 Notably, in these latter subjects, VD sup-
plementation was able to restore muscle strength and prevent 
muscle mass loss.12,13 Since VD deficiency is highly prev-
alent also among advanced cancer patients with cachexia,14 
the encouraging results of VD supplementation on frail el-
derly subjects led to the hypothesis that VD supplementation 
could be used as an anti‐cachexia treatment. A phase II trial 
in which VD was supplemented to six patients with advanced 
prostate cancer showed indeed an improvement of muscle 
strength.15 However, the follow‐up phase III trial with 953 
patients was prematurely stopped after an interim analysis 
showed greater mortality in the supplemented versus placebo 
arm.16 The lack of effectiveness of VD supplementation in 
preventing cancer cachexia‐associated muscle wasting was 
recently demonstrated also in tumour‐bearing animals.17
VD metabolism initiates in the skin with the conver-
sion of 7‐dehydrocholesterol to VD upon ultraviolet expo-
sure. VD is hydroxylated in the liver to 25‐hydroxy‐VD (25 
VD), the major circulating form. 25 VD undergoes another 
hydroxylation in the kidney to 1α,25‐dihydroxy‐VD (1,25 
VD), commonly considered the biologically active form. 
However, 1α‐hydroxylase (encoded by the Cyp27b1 gene), 
the enzyme responsible for the hydroxylation of 25 VD 
to 1,25 VD, is expressed in various tissues, including the 
skeletal muscle,18 providing support for the direct action 
of both 25 VD and 1,25 VD on muscle. Indeed, on skele-
tal muscle‐derived cells, both forms have been reported to 
be active, although sometimes with contrasting results. For 
example, 1,25 VD treatment of C2C12 myoblasts resulted 
in increased VD receptor (VDR) expression, inhibition 
of cell differentiation and proliferation and down‐regula-
tion of myogenin.17-19 In contrast, other studies reported 
that 1,25 VD stimulates myogenesis in satellite cells and 
C2C12 myocytes.20,21
Therefore, further investigation is needed on the effect 
of VD metabolites on skeletal muscle, and here, in partic-
ular, we explored the biological effects and mechanisms 
of action of 25 VD and 1,25 VD on myotubes undergoing 
cancer cell conditioned medium‐ or cytokines‐mediated at-
rophy as a model of in vitro cachexia‐associated muscle 
wasting.
2 |  RESULTS
2.1 | 25 VD, but not 1,25 VD protects C2C12 
myotubes from cytokine‐ and cancer cell 
conditioned medium‐induced atrophy
C2C12 are a widely used system to model in vitro skeletal 
muscle atrophy.22 In particular, treatments of C2C12 myo-
tubes for 24 hours with a combination of TNF‐α and IFNγ 
or IL‐6 mimic cancer‐induced muscle wasting, leading to 
the reduction of myotubes diameters up to 20%. Co‐treat-
ment with 25 VD prevented the decrease in myotube di-
ameter, while 1,25 VD had no protective effects (Figure. 
1A). As a matter of fact, administration of 1,25 VD alone 
induced a 20% reduction in myotube diameters, on the con-
trary, 25 VD had a mild hypertrophic effect, in accordance 
with previously published results.23 Likewise, 25 VD pro-
tected C2C12 myotubes from the atrophy induced by treat-
ment with conditioned medium from Lewis lung carcinoma 
(LLC) cells (Figure 1B).
2.2 | 1,25 VD induces atrophy by increasing 
FoxO3 expression and atrogene induction
In skeletal muscle, excessive activation of ubiquitin‐pro-
teasome leads to muscle loss. Forkhead box O (FoxO) pro-
teins play a central role in regulating the activation of these 
atrophic pathways, in particular by inducing the transcription 
of muscle‐specific E3 ubiquitin ligases, collectively known 
as atrogenes, and of autophagy‐related genes.24 Notably, 1,25 
VD increased FoxO3a protein level (Figure 2A) that, in turn, 
upregulated mRNA expression of Atrogin‐1 and MuRF‐1 
atrogenes (Figure 2B).
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2.3 | 25 VD induces activation of Akt 
signalling pathway and protein synthesis
In agreement with the anti‐atrophic and hypertrophic effect of 
25 VD (Figure 1), an antibody array detecting the relative ex-
pression of phosphorylated proteins showed, within 10 min-
utes of 25 VD treatment, an increase in the activation of Akt/
mTOR protein network associated with protein synthesis. 
This anti‐atrophic signalling persisted, although attenuated, 
also after 24 h of treatment (Figure 3A). We confirmed the 
phosphorylation of Akt by western blotting (Figure 3B) and 
verified if the early activation of Akt was necessary for the 
effect of 25 VD on myotubes by adding to the treatments the 
pharmacologic inhibitor of PI3K/Akt pathway LY294002. 
The complete abrogation of the protective activity of 25 VD 
upon LY294002 treatment (Figure 3C) demonstrated indeed 
the requirement of early activation of Akt pathway for the 
anti‐atrophic effect of 25 VD on myotubes. In addition, co-
herently with 25 VD‐induced activation of Akt signalling, 
25 VD treatment increased protein synthesis, measured as 
puromycin incorporation in SUnSET assay (Figure 3D), and 
promoted FoxO3a phosphorylation (Figure 3E), thus inhibit-
ing its translocation in the nucleus and the transcription of 
atrogenes.
2.4 | 25 VD and 1,25 VD have differential 
effects on the autophagic flux
Autophagy plays a central role in muscle homeostasis by reg-
ulating protein and organelle turnover and, for this reason, 
any perturbation of the autophagic flux may result in tissue 
loss. We, therefore, evaluated if 25 VD and 1,25 VD affected 
C2C12 autophagy by assessing the expression of autophagy‐
related genes Bnip3, Gabarapl1 and Cathepsin L.
Notably, 25 VD did not significantly perturb the expres-
sion of these autophagy‐related genes, while 1,25 VD treat-
ment increased the expression of Bnip3 and Gabarapl1, while 
F I G U R E  1  25 VD, but not 1,25 VD, 
protects C2C12 myotubes from cytokine‐
induced atrophy. Myotube diameters 
were measured after 24 h treatment in 
differentiation medium (DM) with (A) 
100 nmol/L 1,25 VD or 25 VD together 
with 20 ng/mL IL‐6 or 10 ng/mL TNFα/
IFNγ, and (B) 100 nmol/L 25 VD together 
with conditioned medium (CM). Data 
are presented as means ± SEM of three 
independent experiments. *P < 0.05; 




























































F I G U R E  2  1,25 VD atrophic activity involves FoxO3a/atrogenes 
induction. (A) Representative western blot (top) and densitometry 
(bottom) of FoxO3a protein levels in C2C12 myotubes treated with 
100 nmol/L 1,25 VD for 24 h. Expression of atrogenes (B) was 
assessed by real‐time RT‐PCR. Reference line represents the control 
(vehicle‐treated cells). *P < 0.05 vs. control. All treatments were in 
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substantially reducing Cathepsin L expression (Figure 4A), 
suggesting an upsurge of the autophagic flux yet its block in 
the final fusion of autophagosomes with lysosomes.
To assess the occurrence of this autophagic flux block, 
we measured the autophagosomal marker LC3, the lysosomal 
marker LAMP2, and their colocalization in C2C12 myotubes 
in the presence or absence of chloroquine, a treatment known 
to block the autophagic flux. Surprisingly, 25 VD induced 
a strong accumulation of LC3 staining only in chloroquine‐
treated cells, indicating an enhanced autophagic flux, while 
in 1,25 VD‐treated cells LC3‐positivity was already high and 
not further increased by chloroquine, suggesting a block of 
the autophagic flux (Figure 4B and C). Coherently, chlo-
roquine treatment enhanced the formation of autophagoly-
sosomes, seen as LC3‐LAMP2 colocalization, only in 25 
VD‐treated cells (Figure 4B and D).
Given the opposite effects of 25 VD and 1,25 VD on au-
tophagy and in promoting protein synthesis and degradation, 
respectively, we explored the potential involvement of Atf4, 
a transcription factor at the crossroad between anabolic and 
catabolic processes, as it might induce the activation of au-
tophagy‐mTORC1‐amino acid uptake and protein synthesis 
axis.25 We assessed Atf4 expression at different time points 
after treatment with the two VD metabolites and observed 
that 25 VD did not induce any noteworthy change in Atf4 
mRNA, while 1,25 VD caused a significant and persisting 
decrease of Atf4 expression (Figure 4E), suggesting a possi-
ble mechanism of autophagy impairment.
2.5 | VD‐24‐hydroxylase involvement in the 
differential effects of VD metabolites
In vivo, the kidney is the main organ that produces 1,25 
VD; however, the mitochondrial enzyme 1α‐hydroxylase 
(encoded by the gene Cyp27b1) that mediates the produc-
tion of 1,25 VD from 25 VD is expressed by a wide array 
F I G U R E  3  25 VD stimulates anti‐atrophic pathways, protein synthesis, and its protective activity depends on Akt signalling. (A) Relative 
phosphorylation of proteins of the Akt pathway induced by 10 min or 24 h treatment in DM with 100 nmol/L 25 VD through protein array 
analysis. Reference line represents vehicle‐treated cells. *P < 0.05 vs. control. (B) Treatment for 5 min with 100 nmol/L 25 VD enhances AktS473 
phosphorylation. Representative western blot (top) and densitometry (bottom) of three independent experiments. (C) Protein synthesis upon 24 h 
treatment with 100 nmol/L 25 VD was assessed by SUnSET assay. Incorporation of puromycin into newly synthesized proteins was visualized by 
Western blotting and normalized on total proteins detected by Ponceau staining (left). Densitometry of three independent experiments is shown on 
the right part of the panel. (D) Treatment with 10 μmol/L LY294002, an inhibitor of PI3K/Akt pathway, abolishes 25 VD protective effect against 
20 ng/mL IL‐6‐induced atrophy. Myotube diameters were measured as described before. (E) Treatment for 5 min with 100 nmol/L 25 VD enhances 
FoxO3a phosphorylation. Representative western blot (top) and densitometry (bottom) of three independent experiments. All treatment was 
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of tissues and cells, including C2C12 myoblasts and myo-
tubes, supposedly to allow the biological activity of 25 VD 
upon intracellular conversion to 1,25 VD.18 Although in our 
in vitro system exogenously administrations of 25 VD and 
1,25 VD to C2C12 myotubes have divergent effects, appar-
ently, 25 VD needs to be intracellularly converted to 1,25 
VD to exert its anti‐atrophic activity, as silencing of 1α‐hy-
droxylase abrogated the anti‐atrophic effect of 25 VD (Figure 
5A). However, this result is totally in conflict with the pro‐
atrophic effect of 1,25‐VD (Figure 1A). We, therefore, 
hypothesized that Cyp27b1 silencing could affect the expres-
sion of VD‐24‐hydroxylase, the enzyme converting VD me-
tabolites in 24‐hydroxylated products targeted for excretion. 
The altered expression of Cyp24a1 would thus modulate the 
levels of 24‐hydroxylated metabolites that, in the context of 
skeletal muscle, might induce atrophy. Indeed, Cyp27b1 si-
lencing strongly induced the expression of Cyp24a1 (Figure 
5B), and treatment with 24,25‐dihydroxy‐VD (24,25 VD) in-
duces atrophy in C2C12 myotubes (Figure 5C). Accordingly 
with our hypothesis, simultaneous silencing of both Cyp27b1 
and Cyp24a1 restored the protective activity of 25 VD in 
myotubes treated with atrophic stimuli (Figure 5D). We fur-
ther hypothesized that the divergent effects of 25 VD and 
1,25 VD on C2C12 myotubes could be due to a differential 
induction of Cyp24a1. As a matter of fact, both 25 VD and 
1,25 VD induced the expression of Cyp24a1 but at different 
extents (Figure 5E). Treatment with 1,25 VD might result 
in its conversion to a pro‐atrophic 1,24,25 VD metabolite. 
Coherently, silencing of Cyp24a1 attenuated the atrophic ac-
tivity of 1,25 VD (Figure 5F), suggesting that intracellular 
24‐hydroxylation of 1,25 VD mediates its atrophic activity. 
On the contrary, the slighter induction of Cyp24a1 by 25 VD 
could induce a limited amount of 24,25 VD endowed with 
protective activity. Indeed, 24,25 VD elicits in C2C12 oppo-
site outcomes depending on the concentration used, ranging 
from hypertrophic to atrophic effects (Figure 5G).
3 |  DISCUSSION
Although 25 VD has been considered for a long time an 
inactive reservoir of 1,25 VD, a growing body of evidence 
indicates that it has its own biological activities in different 
tissues, including skeletal muscle.23,26-29 The presence of 
Cyp27b1 in skeletal muscle cells18 would suggest, as a mech-
anism of action of 25 VD, its intracellular conversion to 1,25 
VD by 25 VD‐1α‐hydroxylase, a process indeed occurring in 
T cell response to 25 VD.30 However, here we showed that 
25 VD and 1,25 VD have opposite effects on differentiated 
C2C12 myotubes, leading to the inconsistency of such hy-
pothesis. In particular, we demonstrated that 1,25 VD induces 
a sharp reduction of C2C12 myotube diameters, in agreement 
F I G U R E  4  25 VD and 1,25 VD have differential effects on the 
autophagic flux. (A) 24h after treatment with 100 nmol/L of 25 VD 
or 1,25 VD, expression of autophagic genes was assessed by real‐time 
RT‐PCR. Reference line represents control (vehicle‐treated cells). 
*P < 0.05 vs. control. (B) Representative images of LC3‐LAMP2 
immunofluorescence. C2C12 myotubes were treated for 24 h with 
100 nmol/L of 25 VD and 1,25 VD in the presence or absence of 
10 µmol/L of chloroquine (Cq). (C) Percentage of LC3 stained area 
above total myotube area and (D) percentage of LC3 area colocalized 
with LAMP2 above total myotube area. *P < 0.05. (E) Atf4 expression 
was evaluated by real‐time RT‐PCR after 1, 6 and 24 h treatment with 
100 nmol/L of both 25 VD and 1,25 VD. Reference line represents 
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with previously published data.17 Consistently, 1,25 VD 
treatment increased the expression of FoxO3a and the induc-
tion of Atrogin‐1 and MuRF1 atrogenes, a well‐characterized 
atrophic mechanism in skeletal muscle. The finding that VD 
receptor (VDR) directly associates with FoxO proteins and 
enhances FoxO binding to target gene promoters31 suggests 
a further mechanism enhancing 1,25 VD‐promoted atrophic 
effect. Besides being a key regulator of protein breakdown 
through the ubiquitin‐proteasome, FoxO3 also modulates 
the autophagy‐lysosomal proteolytic pathway.24 Basal au-
tophagy is necessary for cellular homeostasis, but its dys-
regulation, either its exacerbated activation or its block, may 
result in atrophy. Treatment of C2C12 myotubes with 1,25 
VD decreased Cathepsin L expression (Figure 4A), a protein 
required for the fusion of autophagosomes with lysosomes, 
thus leading to the accumulation of autophagosomes incapa-
ble of fusing with the lysosomes (Figure 4C) and the eventual 
blockage of the autophagic flux. 1,25 VD‐induced reduction 
of ATF4, a transcription factor that, in stressful conditions 
induces autophagy,32 could concur to this impairment. The 
concomitant enhanced expression of Bnip3 and Gabarapl1 
genes (Figure 4A) suggests a compensatory intensification 
of the early autophagosome formation aimed at maintaining 
a functional autophagic flux. On the contrary, the increased 
autophagic flux upon 25 VD treatment (Figure 4D), could 
occur through a pathway mediated by AMPK (Figure 3A). 
Although excessive autophagy may lead to tissue wast-
ing, this 25 VD‐induced autophagy enhancement could be 
F I G U R E  5  Regulation of VD‐24‐hydroxylase and its role in muscle homeostasis. (A) C2C12 myotubes were transfected with Cyp27b1 
siRNA and, 24h later, were treated with IL‐6 (20 ng/mL) with or without 100 nmol/L 25 VD. Myotube diameters were measured after further 24 h. 
‡P < 0.001. (B) Cyp24a1 expression was evaluated after 48h of Cyp27b1 silencing. *P < 0.05. (C) Myotube diameters were measured after 24 h of 
100 nmol/L 24,25 VD treatment. ‡P < 0.001. (D) C2C12 myotubes were transfected with Cyp27b1 siRNA alone or in combination with Cyp24a1 
siRNA. 24h after silencing, C2C12 myotubes were treated with IL‐6 (20 ng/mL) with or without 100 nmol/L 25 VD and myotube diameters 
measured after further 24 h. †P < 0.01; ‡P < 0.001. (E) Cyp24a1 expression in C2C12 myotubes after 24 h treatment with 100 nmol/L 25 VD, 1,25 
VD, 24,25 VD. *P < 0.05; ‡P < 0.001. (F) C2C12 myotubes were treated with 100 nmol/L 1,25 VD after 24 h of Cyp24a1 silencing. ‡P < 0.001. 
(G) Myotube diameters were measured after 24 h of treatment with increasing concentration of 24,25 VD. ‡P < 0.001. All treatments were in 
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beneficial, likely by increasing the availability of amino acids 
that, in turn, could contribute, together with Akt, to mTORC1 
activation and protein synthesis.
25 VD, on the other hand, showed a protective effect 
against cytokine‐induced atrophy and a mild hypertrophic 
effect when administered alone on C2C12 myotubes. Since 
muscle mass may be seen as the overall balance of anabolic 
and catabolic pathways, we suppose that the Akt pathway‐
mediated hypertrophic effect of 25 VD counterbalances cy-
tokine‐induced atrophy. Phosphorylation of FoxO3a (Figure 
3E) suggests that also the inhibition of atrogene expression 
could be involved in 25 VD anti‐atrophic activity, although in 
the system we used we could not appreciate cytokine‐induced 
atrogene induction.
The differential induction of VDR by 1,25 VD and 25 
VD and the weaker affinity of the latter for VDR itself19,23,33 
may explain the dissimilar effects of these VD metabolites on 
C2C12 myotubes as a divergent VDR‐mediated enhancement 
of FoxO.31 Nevertheless, in this work, we demonstrated the 
involvement of VD‐24‐hydroxylase induction and the trans-
formation of VD metabolites in pro‐atrophic 24‐hydroxylated 
products. Despite the fact that previous studies demonstrate 
that VD metabolites regulate Cyp24a1 expression,19,23 the 
effect of 24‐hydroxylated metabolites on skeletal myotubes 
have not been investigated, yet. Our data show that 24,25 VD 
has a hormetic effect on myotubes, seen as a hypertrophic 
effect at low doses and atrophic effect at higher doses (Figure 
5G). On account of the strongest induction of Cyp24a1 by 
1,25 VD compared to 25 VD (Figure 5E), we hypothesize a 
central role of VD‐24‐hydroxylase in causing the differen-
tial effects of 1,25 VD and 25 VD on skeletal muscle. As it 
happens, Cyp24a1 silencing attenuated the 1,25 VD atrophic 
effect on C2C12 myotubes (Figure 5F). We can speculate 
that, in C2C12 myotubes, 1,25 VD‐triggered expression of 
VD‐24‐hydroxylase converts 1,25 VD in 1,24,25 VD, and that 
this metabolite, similarly to 24,25 VD, has an atrophic effect 
on C2C12 myotubes, though we could not test this hypothe-
sis due to the lack of commercially available formulations of 
this metabolite. The involvement of VD‐24‐hydroxylase also 
explains the incongruous results emerging from the silencing 
of Cyp27b1 used to assess the intracellular conversion of 25 
VD in 1,25 VD, as Cyp27b1 silencing leads to a significant 
increase of Cyp24a1 mRNA expression (Figure 5B). Indeed, 
the idea that an anti‐atrophic compound needed to be trans-
formed in a pro‐atrophic one to elicit its effect was disproved 
by Cyp27b1 silencing‐induced increase of Cyp24a1 mRNA 
expression and by the fact that co‐silencing of Cyp27b1 and 
Cyp24a1 restores 25 VD protective action against atrophic 
stimuli.
Low levels of VD are, together with fatigue and skeletal 
muscle loss, characteristics of cancer patients with cachexia.14 
VD status positively associates with muscle strength, physi-
cal performance, and a lower incidence of falls.34 Therefore, 
VD supplementation has been proposed as a possible pre-
ventive strategy in delaying muscle functional decline in 
several pathological conditions, including cancer cachexia. 
However, VD supplementation was ineffective in preventing 
cancer cachexia‐associated muscle wasting in animals,17 and 
a phase III clinical trial with cachectic patients was prema-
turely halted because of the detrimental effect of VD sup-
plementation.16 Because VD is a steroid, high dose regimens 
are usually proposed in clinical practice on the assumption of 
its storage in adipose tissue followed by a slow release.35,36 
However, high doses of VD do not mirror the physiological 
production of the hormone. Consistently, high VD intakes 
or treatments with very high doses as a bolus (every month 
or twice a year) have paradoxically been associated in sev-
eral studies with adverse events in humans, including an in-
creased incidence of falls and fracture, rates of prostatic and 
pancreatic cancers, and total mortality.35,37-39 In agreement 
with the results of our and others work,23 an up‐regulation of 
Cyp27b1‐ and Cyp24a1‐derived VD metabolites is therefore 
feasible upon high VD intakes.
Overall, this study shows how variously hydroxylated VD 
metabolites and the differential regulation of VD hydroxy-
lases may trigger contrasting effects in C2C12 myotubes, 
thus explaining the lack of effectiveness of VD supplemen-
tation in vivo, both in animal models of cancer cachexia 
and in oncological patients. Our results shed light on other 
mechanisms involved in the failing or contradictory results 
of several clinical trials. In this regard, further studies will 
be necessary before considering VD supplementation for the 
maintenance of skeletal muscle mass in cancer patients.
4 |  MATERIALS AND METHODS
4.1 | Reagents
25 VD and 1,25 VD were purchased from Merck (Burlington, 
Massachusetts, USA). 24,25 VD was from Sigma‐Aldrich 
(Saint Louis, Missouri, USA). IL‐6, TNF‐α, and IFNγ 
were from Peprotech (London, UK). Anti‐tubulin antibody 
was from Sigma‐Aldrich, anti‐phospho‐AktS473, anti‐Akt, 
anti‐ phospho‐FoxO3aT32, anti‐FoxO3a, and anti‐LC3 an-
tibodies were from Cell Signalling Technology (Danvers, 
Massachusetts, USA), anti‐LAMP2 antibody was from 
Abcam (Cambridge, UK), and anti‐puromycin antibody was 
from Merck. All other reagents, unless otherwise stated, were 
from Sigma‐Aldrich.
4.2 | Cell cultures and myotube analysis
C2C12 myoblasts were grown at low density in DMEM (Gibco, 
Thermo Fisher Scientific, Waltham, Massachusetts, USA) 
supplemented with 10% foetal bovine serum (FBS, Gibco, 
Thermo Fisher Scientific), 100 U/mL penicillin, 100 μg/mL 
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streptomycin, and 0.25 μg/mL antimycotic, referred to as 
growth medium (GM). To induce differentiation, cells were 
allowed to become confluent, and the medium was switched 
to differentiation medium (DM), consisting in DMEM sup-
plemented with 2% horse serum, penicillin, streptomycin, and 
antimycotic as described above. Unless otherwise specified, 
myotubes were treated at day 4 of differentiation. Myotube di-
ameters were measured as previously described.40
4.3 | Lewis lung carcinoma conditioned 
medium preparation
Lewis lung carcinoma cells (a kind gift from Prof. Paola 
Costelli, University of Turin) were grown in DMEM with 5% 
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. For 
CM collection, cells were plated at a density of 50 000 cells/
cm2 and, after overnight attachment, the cells were washed 
three times with phosphate‐buffered saline (PBS), followed 
by two washes with serum‐free DMEM, and grown in serum‐
free DMEM containing 100 U/mL penicillin and 100 μg/mL 
streptomycin for 24 hours. The resulting CM was centrifuged 
at 500 g for 10 min, followed by additional centrifugation at 
5000 g for 10 min. The CM was filtered using a 0.2 μm sy-
ringe filter and either used immediately or stored at −80°C. 
LLC CM was diluted at a 1:3 ratio with serum‐free DMEM 
containing 100 U/mL penicillin and 100 μg/mL streptomycin 
for myotube treatment.
4.4 | Cyp27b1 and Cyp24a1 silencing
A quantity of 100 pmol of Cyp27b1 siRNA, Cyp24a1 siRNA 
(Ambion, Thermo Fisher Scientific), or siRNA negative con-
trol sequence (Ambion, Thermo Fisher Scientific) was trans-
fected with Lipofectamine 3000 (Invitrogen, Thermo Fisher 
Scientific) in C2C12 at day 3 of differentiation. Myotubes un-
derwent treatments 24 hours later. Transfection of myotubes 
with Block‐iT (Invitrogen, Thermo Fisher Scientific) was used 
to assess transfection efficiency, which was always >90%.
4.5 | RNA extraction and analysis
Total RNA from myotubes was extracted by RNAzol (Sigma‐
Aldrich). The RNA was retro‐transcribed with High‐capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, 
Thermo Fisher Scientific) and real‐time PCR was performed 
with the StepOnePlus Real‐time PCR System (Applied 
Biosystems, Thermo Fisher Scientific), using the following 
TaqMan probes (Thermo Fisher Scientific): Mm00499518_
m1 (Fbxo32, Atrogin‐1/MAFbx), Mm01185221_m1 
(Trim63, MuRF1), Mm00515597_m1 (Ctsl, Cathepsin L), 
Mm01275600_g1 (Bnip3), Mm00457880_m1 (Gabarapl1), 
Mm01197698_m1 (Gusb), Mm00487244_m1 (Cyp24a1), 
Mm00515325_g1 (Atf4).
4.6 | Western Blotting
At the end of the indicated treatments, cells were washed in 
ice‐cold PBS and solubilized with a lysis buffer containing 1% 
Triton X‐100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, 1 mmol/L EDTA, 1 mmol/L EGTA, 50 mmol/L NaF, 
160 mmol/L NaCl, 20mM Tris‐HCl, pH 7.4, and supplemented 
with protease inhibitor cocktail. Lysates were stirred at 4°C 
for 15 min and centrifuged at 15 000 g for 15 minutes at 4°C. 
Protein concentration was determined by BCA protein assay 
kit (Thermo Fisher Scientific). Proteins (10‐20 μg protein/lane) 
were separated by 10% SDS‐PAGE and transferred to polyvi-
nylidene difluoride filters (PVDF) (Hybond‐P; GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). Membranes were 
saturated with 4% bovine serum albumin (BSA), incubated 
with the primary antibodies overnight, washed with Tris‐
buffered saline‐0.1% Tween, incubated with the appropriate 
secondary antibody (Invitrogen, Thermo Fisher Scientific), vis-
ualized with Western Lightning Chemiluminescence Reagent 
Plus (PerkinElmer Life and Analytical Sciences, Waltham, 
Massachusetts, USA), acquired with ChemiDoc Touch (Bio‐
Rad, Hercules, California, USA), and analysed with ImageLab 
(Bio‐Rad). After anti‐phospho‐antibodies, membranes were 
stripped with Restore Plus Western blot stripping buffer 
(Thermo Fisher Scientific) and reblotted with the correspond-
ing total protein antibodies.
4.7 | Immunofluorescence
For LAMP2 and LC3 detection, C2C12 myotubes were 
fixed in 4% paraformaldehyde for 10 minutes, washed with 
PBS, permeabilized with HEPES‐TRITON X‐100 0.5% for 
5 minutes, and washed two times with PBS‐0.2% BSA. For 
blocking the unspecific binding sites, cells were incubated 
in 2% BSA for 15 minutes at RT. LC3‐ and LAMP2‐posi-
tive puncta were evaluated by incubation for 30 min-
utes with rabbit anti‐LAMP2 (1:25) and mouse anti‐LC3 
(1:100), followed by the appropriate Alexa Fluor Dyes‐
conjugated secondary antibodies (546 anti‐mouse, 488 
anti‐rabbit; Thermo Fisher Scientific). Nuclei were coun-
terstained with TO‐PRO‐3 iodide (1:100, Thermo Fisher 
Scientific). Images were acquired with Leica confocal 
microscope TCS SP2 (Wetzlar, Germany) equipped with 
LCS Leica confocal software, using a 63X objective, NA 
5 1.32, and fluorescence signals, normalized to the area of 
myotubes, for LC3, LAMP2, and their colocalization were 
quantified with ImageJ software.
4.8 | AKT pathway phosphorylation array
Mouse AKT pathway phosphorylation array C1 was pur-
chased from RayBiotech, Inc (Norcross, Georgia, USA) and 
used according to manufacturer instructions.
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4.9 | SUnSET protein synthesis assay
Differentiated myotubes were treated with 100 nmol/L 25 
VD in DM for 24 hours, and, 30 minutes before cell lysis, 
500 ng/mL puromycin was added to the medium. After west-
ern blotting with an anti‐puromycin antibody, membranes 
were stained with Ponceau S red to visualize total proteins. 
Both western blots and stained membranes were acquired 
with ChemiDoc Touch (Bio‐Rad, Hercules, California, 
USA), and analysed with ImageLab (Bio‐Rad).
4.10 | Statistical analysis
Data are presented as the mean ± SEM The variation among 
groups was evaluated using ANOVA test. Statistical signifi-
cance was assumed for P < 0.05. All statistical analyses were 
performed with GraphPad Prism 6 for OS Windows.
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After having demonstrated that 25 VD and 1,25 VD have opposite effects on C2C12 myotubes, likely 
via differential modulation of 24-hydroxylase, and that 24,25 VD itself has either atrophic or 
hypertrophic effects, depending on its concentration (Sustova et al., 2019), thus reinforcing the idea 
that all VD metabolites, and not only 1,25VD, might be biologically active (Raisz et al., 1980; Eisman 
et al., 2014), we wondered if also cholecalciferol (VD3), the non-hydroxylated upstream metabolite, 
could have a biological effect on muscle cells. 
In the in vitro muscle model of C2C12 myotubes induced to undergo atrophy with IL-6 treatment, we 
demonstrated the protective activity of VD3. The lack of expression, in C2C12 myotubes, of the 
hydroxylase transforming VD3 suggests that VD3 protective effect on skeletal muscle are direct. 
Similarly to 25VD, VD3 could prevent atrophy through enhancing the autophagic flux, while it does 
not significantly affect protein synthesis. Moreover, we demonstrated that VDR is required for VD3 
biological activity, hinting that VDR could bind, besides 1,25VD and 25VD, also their non-
hydroxylated precursor. Finally, we showed that VD3 was unable to protect from dexamethasone-
induced atrophy, suggesting a limited anti-atrophic potential of cholecalciferol, depending on the 
underlying cause of muscle wasting. Overall, our results widen the horizons of the extra-skeletal 
effects of vitamin D, as well as the potential therapeutic benefits and limits of vitamin D 
supplementation.  
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We previously determined that different vitamin D metabolites can have opposite effects on C2C12 
myotubes, depending on the sites of hydroxylation or doses. This study aimed to clarify whether also 
cholecalciferol (VD3), the non-hydroxylated upstream metabolite, has a direct effect on muscle cells. 
Assessing the effects of VD3 treatment on mouse C2C12 skeletal muscle myotubes undergoing 
atrophy induced by IL6, we demonstrated that VD3 has a protective action, preserving C2C12 
myotubes size, likely through enhancing the autophagic flux. The lack, in C2C12 myotubes, of the 
hydroxylase transforming VD3 in the anti-atrophic 25VD metabolite, suggests that VD3 may have a 
direct biological activity on the skeletal muscle. Furthermore, the protective action of VD3 depended 
on VDR, implying that also VD3 might bind and activate VDR.  




Skeletal muscle wasting may occur in several physio-pathological conditions and represents one of 
the main overlapping features between the physiological age-related sarcopenia and cachexia, which 
often associates with an underlying disease, such as cancer, especially in the terminally ill patients.  
In both cases, the occurrence of chronic systemic inflammation may directly contribute to the loss of 
skeletal muscle mass and functionality [1–5]. 
Another feature often associated with both muscle wasting-inducing conditions is an important 
reduction of vitamin D3, seen as decreased 25(OH)D3 (25-hydroxycholecalciferol, hereafter 25VD) 
circulating levels [6,7]. 
In humans, vitamin D3 synthesis begins with skin exposure to ultraviolet B radiation and the 
consequent photochemical conversion of the precursor, 7-dehydrocholesterol (pro-vitamin D3), in 
pre-vitamin D3. Through thermal isomerization, pre-vitamin D3 is converted to vitamin D3 
(cholecalciferol, hereafter VD3), which is hydroxylated in the liver by the 25-hydroxylases (25-
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OHases encoded by CYP27A1 and CYP2R1 genes); the resultant 25VD is further converted in 
1,25(OH)2D3 (1,25-dihydroxy vitamin D3 or calcitriol, hereafter 1,25VD) in the kidney by 1α-
hydroxylase (1α-OHase, encoded by the CYP27B1 gene). Lastly, the 24-hydroxylase encoded by the 
gene CYP24A1 catalyzes the conversion of both 25VD and 1,25VD into 24-hydroxylated products 
targeted for inactivation and excretion.  
1,25VD exerts its biological activities through the binding to vitamin D receptor (VDR), inducing the 
heterodimerization of VDR with the retinoic acid receptor RXR, the recruitment of various 
coregulators, and the binding of this complex to specific regions on DNA. Though the bone is the 
best-known target of vitamin D, VDR is almost ubiquitously expressed through the cells and tissues 
of the body, suggesting that vitamin D has wide pleiotropic activities. Likewise, the widespread extra-
renal expression of the CYP27B1 hydroxylase suggests that 25VD could be locally converted to 
1,25VD, thus providing a mechanism explaining the ever-growing observations of 25VD-elicited 
biological activities [8,9]. Nevertheless, we have demonstrated that, in C2C12 myotubes, 25VD has 
a biological anti-atrophic activity that does not depend on its intracellular conversion to 1,25VD. 
Unexpectedly, in this in vitro model of skeletal muscle, 25VD and 1,25VD have antithetical effects, 
likely via differential modulation of 24-hydroxylase [10]. Furthermore, we showed that, on C2C12 
myotubes, 24,25(OH)2D3 (24,25VD) itself could have divergent effects, either atrophic or 
hypertrophic, depending on its concentration. These observations are in accordance with and 
strengthen the idea that all vitamin D3 metabolites, and not only 1,25VD, might be biologically active 
[11,12]. Proceeding with this view, here we explored the hypothesis that VD3 as well could have a 









VD3 treatment protects C2C12 myotubes from IL-6 induced atrophy   
To assess whether VD3 could have protective activity in the skeletal muscle, we mimicked in vitro 
the condition of inflammation-prompted muscle wasting by treating murine C2C12-derived myotubes 
with the pro-atrophic cytokine interleukin-6 (IL-6) [10]. C2C12 myotubes incubated for 24 hours 
with 20 ng/ml IL-6 underwent a consistent atrophy, appraised as a reduction of 20% in myotube 
thickness (Figure 1A). Co-treatment with VD3 prevented the reduction of myotube diameter in a 
dose-dependent manner, starting from 1 nM concentrations. At concentrations of 10 and 100 nM, 
VD3 completely blocked the atrophic effect of IL-6 (Figure 1A). The supplementation of VD3 alone 
had no evident effects on C2C12 myotube size (Figure 1B). 
 
VD3 stimulates the autophagic flux in C2C12 myotubes 
Skeletal muscle homeostasis depends on the balance between anabolic and catabolic processes. 
Coherently with the lack of effect on myotube diameters (Figure 1B), VD3 did not stimulate protein 
synthesis, although we observed a mild, not significant increase in puromycin incorporation in 
SUnSET assay (Figure 2A). We, therefore, investigated whether VD3 could affect autophagy, another 
mechanism that can regulate muscle homeostasis by regulating protein and organelle turnover 
[13,14]. To assess the effect of VD3 on the autophagic flux, we measured the colocalization of the 
autophagosomal marker LC3 with the lysosomal marker LAMP2 in C2C12 myotubes in the presence 
or absence of chloroquine, a blocker of the autophagic flux. We observed that VD3 induced a drastic 
accumulation of LC3‐LAMP2 co-staining only in cells co-treated with chloroquine, denoting an 
increased formation of autophagolysosomes, indicative of an enhancement of the autophagic flux 
(Figure 2B).  
 
34 
VD3 anti-atrophic activity is VDR-dependent but does not depend on intracellular conversion 
to 25VD   
The complexity of vitamin D biological activity is further complicated by the ability of distinct 
vitamin D metabolites to modulate the expression of the hydroxylases involved in vitamin D 
metabolism and of VDR [15]. To explore if the hitherto observed effects of VD3 on C2C12 myotubes 
could depend on its transformation on other metabolites with already proven biological activity, we 
assessed the expression of the main players of vitamin D metabolism upon VD3 treatment. In 
particular,  as we have previously demonstrated that 25 VD has a powerful anti-atrophic activity in 
C2C12 myotubes treated with pro-cachectic cytokines, including IL-6 [10], we explored the 
hypothesis that the observed anti-atrophic effect of VD3 could be due to its intracellular conversion 
to 25 VD in C2C12 myotubes. In vivo, VD3 is hydroxylated in the liver by 25-hydroxylases (in 
mouse, mainly by Cyp2r1; Ohyama & Shinki, 2016; Thacher & Levine, 2017) to yield 25 VD. Using 
murine liver as a positive control, we found that the Cyp2r1 was not expressed in C2C12 myotubes, 
neither basally nor upon stimulation with VD3 or IL6 (data not shown), providing evidence for a 
direct biological action of VD3 on C2C12 myotubes.  
In addition, we found that, similarly to 25VD and 1,25VD [18], VD3 did not affect the expression of 
Cyp27b1 (Figure 3A). However, differently from 25VD and 1,25VD metabolites [10,18], VD3 did 
not modulate the expression of 24-hydroxylase Cyp24a1 (Figure 3B), nor that of Vdr (Figure 3C). 
Also, VD3 had no effect on the expression of Pdia3, the gene encoding for the 1,25D3-MARRS 
(Membrane Associated, Rapid Response Steroid binding), an alternative vitamin D receptor regarded 
as the one mediating the membrane-initiated signaling of 1,25VD3 (Figure 3D).  
 
VD3 anti-atrophic activity is VDR-dependent 
Although VD3 does not modulate the expression of Vdr (Figure 3C), the silencing of Vdr completely 
abrogated the protective activity of VD3 against IL6-induced atrophy (Figure 4A), indicating that 
VDR mediates VD3 anti-atrophic activity in C2C12 myotubes. On the contrary, 1,25D3-MARRS 
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receptor is not involved in VD3 anti-atrophic action, as the silencing of Pdia3 did not affect the 
activity of VD3 (Figure 4B). 
 
VD3 does not protect C2C12 myotubes from dexamethasone-induced atrophy 
To investigate if VD3 could have a broad anti-atrophic activity, we assessed its effect by co-treating 
C2C12 myotubes undergoing atrophy upon treatment with dexamethasone, a synthetic glucocorticoid 
that induces muscle protein degradation via the activation of the ubiquitin-proteasome system (UPS) 
[19]. Myotubes were treated with 5 μM dexamethasone for 24 h in the presence or absence of 100 
nM VD3. Treatment with dexamethasone reduced myotube diameters by 10% and induced the 
muscle-specific ubiquitin ligase Atrogin-1 (MAFbx) expression. VD3 was not able to impair this 
atrophy (Figure 5A and B), indicating that VD3 ability to counteract muscle atrophy is limited. 
 
DISCUSSION 
The impact of vitamin D on muscle morphology and functionality has been largely investigated, and 
vitamin D deficiency has been implicated in pathological conditions such as frailty and sarcopenia in 
the elders and cachexia in cancer patients [6,20]. Even though the deficiency of vitamin D clearly 
correlates with muscle condition impairment, the effectiveness of vitamin D supplementation depends 
on the context of use. In fact, a relevant number of epidemiological studies have suggested the 
potential role of vitamin D intake in order to maintain or improve muscle strength and function in 
older people [21]. On the other hand, the efficacy of VD supplementation in cancer cachexia remains 
non-conclusive [20].  
In our previous attempt to better understand these different biological responses in the skeletal muscle 
to vitamin D supplementation, we realized that, in vitro, different vitamin D metabolites have 
distinctive activities. In particular, we conjectured that a different extent of 24-hydroxylase 
modulation by 25VD and 1,25VD results in divergent effects on C2C12 myotubes, being 25VD 
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protective against cytokine-induced atrophy and 1,25VD atrophic per se. Furthermore, 24,25VD 
itself can either protect or induce atrophy, depending on its concentration [10].  
Here, we showed that also the un-hydroxylated VD3 could prevent IL-6-induced atrophy in C2C12 
myotubes (Figure 1). Notably, the absence in these cells, either in unstimulated condition or upon 
atrophic stimuli, of Cyp2r1, the principal vitamin D 25-hydroxylase in mice [16,17], rules out an 
intracellular conversion of VD3 in 25VD, whose anti-atrophic activity has already been demonstrated 
[10] and implies a direct activity of VD3 in C2C12 myotubes. In addition, the loss of anti-atrophic 
activity upon silencing of Vdr (Figure 4A) suggests that VDR could also bind VD3, in addition to 
1,25VD and 25VD [22], although specific binding studies should be performed to confirm this 
hypothesis and to determine the binding affinity.  
Our data indicate that the anti-atrophic activity of VD3 is not generic but depends on the stimulus 
inducing atrophy. Indeed, VD3 was unable to protect from dexamethasone-induced atrophy and to 
prevent the induction of the muscle-specific ubiquitin ligases Atrogin-1 (Figure 4). As the ability of 
IL-6 to induce Atrogin-1 remain debated, with several works reporting contrasting finding [23], we 
can speculate that VD3 can protect from stimuli that do not involve, as the primary mechanism, the 
induction of atrogenes (muscle-specific ubiquitin ligases) and activation of the proteasome system. 
Another reason for the lack of protection against dexamethasone-induced atrophy might lie in the 
heterodimerization of the glucocorticoid receptor (GR) with RXR, the main partner for VDR 
heterodimerization upon ligand binding. GR-RXR dimerization occurs in the case of dexamethasone-
induced death of murine T-cells and thymocytes [24]. In the light of the involvement of VDR in the 
anti-atrophic activity of VD3 (Figure 4A), we can speculate that dexamethasone signaling could 
induce the dimerization of GR with RXR, thus preventing the formation of VDR-RXR complex and 
the anti-atrophic activity of VD3. Furthermore, the strong GR activation induced by dexamethasone 
could trap coregulators like steroid receptor coactivator-1 (SRC-1), modifying the mutual binding to 
glucocorticoid- and vitamin D-responsive elements (GREs and VDREs, respectively) on DNA and, 
consequently, the activation/inhibition of specific genes [25–27]. 
37 
On the other hand, IL-6-induced muscle atrophy depends on the activation of STAT3 [28] that, in 
turn, leads to the inhibition of autophagosome formation and autophagy [29,30]. Autophagy is 
essential in maintaining muscle homeostasis through the elimination of defective proteins and the 
recycling of amino acids [31], and its inhibition may result in muscle weakness and atrophy [14]. 
Coherently, VD3 could overcome the IL-6-mediated inhibition of autophagy through boosting the 
autophagic flux (Figure 2B). 
Collectively, our findings suggest that VD3 supplementation in vivo -where it is physiologically 
converted in 25VD, 1,25VD, and 24-hydroxylated products- can result in a combination of effects 
due to the simultaneous action of different vitamin D metabolites, each of which with its own pro- or 
anti-atrophic activity [10]. Moreover, although C2C12 myotubes do not express Cyp2r1, this 25-
hydroxylase is present in the whole muscle [32,33], thus possibly transforming VD3 in 25VD. 
Although VD3 did not modulate the expression of the other hydroxylases involved in vitamin D 
metabolism (Figure 3), some of those may be modulated by other [10,18] and by systemic 
inflammation [34] in a tissue-specific manner, further raveling the scenario and providing a putative 
explanation for the contrasting outcomes of VD3 supplementation in different conditions. In 
conclusion, our findings suggest the need to assess, before VD3 supplementation in vivo, the levels 
of as many as possible vitamin D metabolites as a readout of the activity of different hydroxylases, 
thus avoiding the increase of the pro-atrophic metabolites. Also, the design of VD3-derived not-
hydroxylable molecules that maintain the anti-atrophic property of VD3 preventing the sequential 
hydroxylations that could result in pro-atrophic molecules might represent a prominent strategy to 























Figure 1. VD3 protects C2C12 myotubes from IL-6-induced atrophy. (A) Myotube diameters were measured after 
24h treatment in serum-free medium with 20 ng/ml IL-6 alone or in combination with decreasing concentrations (100 – 
0.01 nM) of VD3. At the bottom of the panel, representative phase-contrast images of differentiated myotubes after 24h 
of treatment with IL-6 in the absence or presence of 100nM VD3. (B) Myotube diameters were measured after 24h 



















Figure 2. VD3 does not stimulate protein synthesis but intensify the autophagic flux. (A) Protein synthesis upon 24h 
treatment with 20 ng/ml IL-6 in the presence or absence of 100nM VD3 was evaluated by SUnSET assay. Incorporation 
of puromycin into newly synthesized proteins was visualized by Western blotting and normalized on total proteins 
detected by Ponceau staining (representative images on the left of the panel). Densitometry of three experiments is shown 
on the right part of the panel. (B) C2C12 myotubes in DM were treated for 24h with100nmol/L VD3 in the presence and 
absence of 10µmol/L of chloroquine (CLQ). LC3 (autophagosome marker) and LAMP2 (lysosomal marker) were 
detected by immunofluorescence. Autophagic flux was assessed by quantifying the colocalization of LC3-LAMP2 in the 
presence vs. absence of CLQ. On the left of the panel, representative images; on the right, percentage of LC3 area 
















Figure 3. VD3 did not alter the expression of hydroxylases and receptors involved in vitamin D metabolism and 
activity. C2C12 myotubes were treated in serum-free medium with VD3 for 24h, and mRNA levels of (A) Cyp27b1, (B) 
Cyp24a1, (C) Vdr, and (D) Pdia3 were assayed by real-time PCR, using Gusb as the housekeeping gene. in Data are 
presented as the mean ± SEM of three independent experiments. *P < 0.05.  
  
Figure 4. VDR, but not 1,25D3-MARRS (Pdia3), mediates VD3 anti-atrophic activity. C2C12 myotubes were 
transfected with (A) Vdr or (B) Pdia3 specific siRNAs. 24h after silencing, C2C12 myotubes were treated with 20ng/mL 
IL-6 in the absence or presence of 100 nM VD3 and myotube diameters measured after further 24h. Data are presented 











Figure 5. VD3 does not protect myotubes against atrophy induced by dexamethasone. (A) Myotube diameters were 
measured after 24h treatment with 5 µM dexamethasone (DEXA) alone or in combination with 100 nM VD3. (B) 
Expression of Atrogin-1 (Fbxo32) was assessed by real-time RT-PCR. Data are presented as the mean ± SEM. ** P 
<0.01.  
 
MATERIALS AND METHODS 
 
Reagents 
VD3 was purchased from Cayman Chemicals (Ann Arbor, Michigan, USA) and dissolved in ethanol. 
IL‐6 was from Peprotech (London, UK). Water-soluble dexamethasone (DEXA) was from Merck 
Life Science (Milan, Italy). The anti‐LC3 antibody was from Proteintech (Rosemont, Illinois, USA), 
the anti‐LAMP2 antibody was from Abcam (Cambridge, UK), and the anti‐puromycin antibody was 
from Merck Life Science. All other reagents, unless otherwise stated, were from Merck Life Science. 
 
Cell cultures and myotube analysis 
C2C12 myoblasts were grown at low density in DMEM (Gibco, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Thermo Fisher 
Scientific), 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL antimycotic. To induce 
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differentiation, cells were allowed to become confluent, and the medium was switched to 
differentiation medium (DM), consisting in DMEM supplemented with 2% horse serum (GE 
Healthcare Bio-Sciences, Uppsala, Sweden), penicillin, streptomycin, and antimycotic as described 
above. Unless otherwise specified, myotubes were treated after 4 days of differentiation in serum-
free medium. Control cells were treated with ethanol. Myotube diameters were measured as 
previously described [35].  
 
Western Blotting 
At the end of the indicated treatments, cells were washed in ice‐cold PBS and solubilized with a lysis 
buffer containing 1% Triton X‐100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 
1 mmol/L EDTA, 1 mmol/L EGTA, 50 mmol/L NaF, 160 mmol/L NaCl, 20mM Tris‐HCl, pH 7.4, 
and supplemented with protease inhibitor cocktail. Lysates were stirred at 4°C for 15 min and 
centrifuged at 15 000 g for 15 minutes at 4°C. Protein concentration was determined by BCA protein 
assay kit (Thermo Fisher Scientific). Proteins (10‐20 μg protein/lane) were separated by 10% SDS‐
PAGE and transferred to polyvinylidene difluoride filters (PVDF) (Hybond‐P; GE Healthcare, Little 
Chalfont, Buckinghamshire, UK). Membranes were saturated with 4% bovine serum albumin (BSA), 
incubated with the primary antibodies overnight, washed with Tris buffered saline‐0.1% Tween, 
incubated with the appropriate secondary antibody (Invitrogen, Thermo Fisher Scientific), visualized 
with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life and Analytical 
Sciences, Waltham, Massachusetts, USA), acquired with ChemiDoc Touch (BioRad, Hercules, 
California, USA), and analyzed with ImageLab (Bio‐Rad). 
 
SUnSET protein synthesis assay 
Protein synthesis was evaluated by SUnSET assay [36]. Differentiated myotubes were treated with 
100 nM VD3 in serum-free medium for 24 hours, and, 30 minutes before cell lysis, 500 ng/mL 
puromycin was added to the medium. After western blotting with an anti‐puromycin antibody, 
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membranes were stained with Ponceau S red to visualize total proteins. Both western blots and stained 
membranes were acquired with ChemiDoc Touch (Bio‐Rad, Hercules, California, USA), and 
analysed with ImageLab (Bio‐Rad). 
 
Immunofluorescence 
For LAMP2 and LC3 detection, C2C12 myotubes were fixed in 4% paraformaldehyde for 
10 minutes, washed with PBS, permeabilized with HEPES‐TRITON X‐100 0.5% for 5 minutes, and 
washed two times with PBS‐0.2% BSA. For blocking the unspecific binding sites, cells were 
incubated in 4% BSA for 1 h at RT. LC3‐ and LAMP2‐positive puncta were evaluated by incubation 
for 1 h with rat anti‐LAMP2 (1:100) and rabbit anti‐LC3 (1:100), followed by the appropriate Alexa 
Fluor Dyes-conjugated secondary antibodies (546 anti‐mouse 1:400, 488 anti‐rabbit 1:400; Thermo 
Fisher Scientific). Nuclei were counterstained with DAPI (1:100, Thermo Fisher Scientific). Images 
were acquired with a Leica TCS SP8 confocal laser scanning microscope (Leica, Wetzlar, Germany) 
equipped with LCS Leica confocal software, using a 63X objective, NA 5 1.32, and fluorescence 
signals, normalized to the area of myotubes, for LC3, LAMP2, and their colocalization were 
quantified with ImageJ software. 
 
RNA extraction and analysis 
Total RNA from myotubes was extracted by RNAzol (SigmaAldrich). The RNA was retro‐
transcribed with High‐capacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermo 
Fisher Scientific) and real‐time PCR was performed with the StepOnePlus Real‐time PCR System 
(Applied Biosystems, Thermo Fisher Scientific), using the following TaqMan probes (Thermo Fisher 
Scientific): Mm00499518_ m1 (Fbxo32, Atrogin‐1/MAFbx), Mm00487244_m1 (Cyp24a1), 
Mm01165918_g1 (Cyp27b1), Mm00437297_m1 (Vdr), Mm00433130_m1 (Pdia3), 
Mm01159413_m1 (Cyp2r1), Mm01197698_m1 (Gusb). 
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VDR and PDIA3 silencing 
A concentration of 10 nM of Vdr siRNA, Pdia3 siRNA (Integrated DNA Technologies), or siRNA 
negative control sequence (Integrated DNA Technologies) was transfected with Lipofectamine 3000 
(Invitrogen, Thermo Fisher Scientific) in C2C12 at day 3 of differentiation. Myotubes underwent 
treatments with IL6 and VD3 24 hours later. Transfection of myotubes with Block‐iT (Invitrogen, 




Data are presented as the mean ± SEM. Outliers in the measurements were identified by mean of the 
interquartile range (IQR), as either below Q1 − 1.5 IQR or above Q3 + 1.5 IQR, and excluded from 
the analysis.  The variation among groups was evaluated using ANOVA test followed by Tukey’s 
Multiple comparisons test unless otherwise stated. Statistical significance was assumed for P < 0.05. 
All statistical analyses were performed with GraphPad Prism 6. 
 
ABBREVIATIONS 
1,25D3-MARRS: Membrane Associated, Rapid Response Steroid binding 
1,25VD:  1,25-dihydroxy vitamin D3, 1,25(OH)2D3, calcitriol 
1α-OHase:  1α-hydroxylase 
24,25VD:  24,25-dihydroxy vitamin D3, 24,25(OH)2D3,  
25-OHases:  25-hydroxylases 
25VD:   25-hydroxycholecalciferol, 25(OH)D3 
BCA:   Bicinchoninic acid 
BSA:   bovine serum albumin 
DAPI:   4′,6-diamidino-2-phenylindole 
DEXA:   dexamethasone  
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DM:   differentiation medium 
DMEM:  Dulbecco’s Modified Eagle Medium 
EDTA:  Ethylenediaminetetraacetic acid 
EGTA:  Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
GR:   Glucocorticoid Receptor 
GREs:   Glucocorticoid-Responsive Elements 
HEPES:  4-(2-HydroxyEthyl)-1-PiperazineEthanesulfonic Acid 
IL-6:   Interleukin 6  
IQR:   interquartile range 
LAMP2:  Lysosomal-Associated Membrane Protein 2 
LC3:   Light Chain 3 
MAFbx:  Muscle Atrophy F-box 
PBS:   Phosphate Buffered Saline 
PVDF:   polyvinylidene difluoride filters 
RT:   room temperature 
RXR:   retinoic acid receptor 
SDS‐PAGE:  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SEM:   Standard error of the mean 
SRC-1:   Steroid Receptor Coactivator-1 
STAT3:  Signal transducer and activator of transcription 3 
SUnSET:  SUrface SEnsing of Translation 
Tris:   2-Amino-2-(hydroxymethyl)-1,3-propanediol 
UPS:   Ubiquitin-Proteasome System 
VD:   Vitamin D 
VD3:   Cholecalciferol, Vitamin D3, D3, VD3 
VDR:   Vitamin D receptor 
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VDREs:  Vitamin D-Responsive Elements 
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Vitamin D and muscle homeostasis - Unpublished data  
Low VD circulating levels characterize both elderly sarcopenic subjects and cachectic oncologic 
patients (Janssen et al., 2002; Mosekilde, 2005; Dev et al, 2011), and VD status positively correlates 
with muscle strength as well (Beaudart et al., 2014; Iolascon et al. 2017). However, VD 
supplementation leads to different outcomes depending on the context of use, resulting a good 
strategy to counteract aged-related muscle wasting but not cancer cachexia-associated muscle atrophy 
(Remelli et al., 2019; Garcia et al., 2019). We demonstrated that un-hydroxylated VD3 and 25 VD protect 
C2C12 myotubes from cytokine-induced atrophy, while 1,25 induces atrophy. Moreover, 24,25 VD 
exerts either protective or atrophic effect depending on concentration. The observation that opposite 
effect of VD metabolites on C2C12 could be due to different modulation of 24-hydroxilase by 25 VD 
and 1,25, prompted to hypothesizes that VD hydroxylase system modulation in vivo may profoundly 
affect VD supplementation outcome.   
Preliminary results obtained from the analysis of VD hydroxylases in several anatomic districts of 
cachectic and sarcopenic mice encourage this hypothesis. 
In accordance with the evidence that 25-hydroxilase is constitutive expressed in liver and subjected 
to just a little feedback regulation (Omdahl et al., 2002; Girgis et al., 2013), there are no significant 
differences in the hepatic expression of the aforementioned enzyme between the experimental 
analyzed groups (Fig. a).  
Interestingly, in kidney, the main organ responsible for the conversion of 25 VD in 1,25 VD, the 
expression on 1-α-hydroxylase is dramatically higher in tumor-bearing animals then in control and 
sarcopenic mice (Fig. b). Furthermore, the expression of 24-hydroxilase is deregulated as well, 
resulting significantly lower in cachectic mice compared to control (Fig. c). In Tibialis Anterior, 1-α-
hydroxylase expression pattern perfectly mirror what has been observed in kidney (Fig. d), indicating 
that different pathophysiologic condition might be characterized by a different status of VD 
hydroxylases.   
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As a further confirmation, in vitro 1-α-hydroxylase expression increases just upon stimuli mimicking 





VD hydroxylases are dysregulated in cachectic but not in old mice. VD hydroxylase and VDR expression was 
evaluated in three experimental group: control mice (CTR), 24-month-old mice (24m) and tumor bearing mice injected 
with LLC.  (a) Cyp2R1 expression in liver. In kidney, Cyp27b1 (b) and Cyp24a1 (c) expression was assessed. Cyp27b1 
expression levels in muscle were checked both ex vivo in Tibialis anterior (d) and in vitro in C2c12 myotubes (f). (e) 
VDR expression was evaluated in Tibialis anterior. *P<0.05. 
 
Our preliminary data might suggest that in elderly the not altered hydroxylase expression pattern 
allows a physiologic VD metabolism, inducing VD circulating level rescue and determining a positive 
outcome of treatment. While the lack of effectiveness of VD supplementation to counteract cancer 
cachexia-associated muscle wasting could be due to a dysregulated VD metabolism, that in turn may 
lead even to an increased concentration of pro-atrophic metabolites.  
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In this regard, evaluating VD metabolites concentration both in cancer cachexia and sarcopenia 
animal models after VD administration, could help clarifying if supplemented VD is processed 
differentially based on context, proposing new insights for clinical practice. Moreover, our findings 
might represent a starting point to design new drugs with restricted hydroxylability to overcome the 
limitations of VD3 supplementation in some pathological conditions.   
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Ghrelin  
Ghrelin is a circulating 28-aa hormone, mainly produced by X/A-like cells in the oxyntic glands of 
the gastric mucosa, discovered as an endogenous ligand of the growth hormone secretagogue receptor 
1a (GHSR1a), a seven-transmembrane G-protein-coupled receptor (GPCR)  (Kojima et al., 1999; 
Howard et al., 1996)  
The human ghrelin gene, GHRL, is localized on chromosome 3p25-26 (Kojima and Kangawa, 2005) 
and encodes for preproghrelin, consisting of 117 amino acids and post-transcriptionally processed 
into pro-ghrelin (Labarthe et al., 2014). Prohormone convertase (PC) 1/3 is the endoprotease 
responsible for the intracellular conversion of proghrelin to ghrelin (Zhu et al., 2006).  
Ghrelin exists in two major different forms: acylated (AG) and unacylated (UnAG). During protein 
maturation, a portion of the ghrelin pool undergoes a post-translational octanoacylation on serine 3 
residue of the mature hormone. This unique post-translational modification is catalyzed by the 
enzyme ghrelin O-acyl-transferase (GOAT) within the endoplasmic reticulum of ghrelin cells 
(Gutierrez et al., 2008; Yang et al., 2008) and it is necessary for the GHSR1a binding (Kojima et al., 
1999) (Fig. 7). AG, through GHSR1a, induces a strong release of growth hormone (GH), stimulates 
food intake, modulate glucose metabolism, increases body weight and adiposity (Kojima et al., 1999; 
Kohno et al., 2003; Reimer et al., 2003, Broglio et al., 2001; Dezaki et al., 2004).  UnAG, which is 
more abundant in plasma than AG, does not bind to GHSR1a, does not induce GH release and has no 
direct effects on food intake, but it shares with AG several biological activities independently of 
GHSR1a, reliant to a yet unidentified receptor (Porporato et al. 2013). Both AG and UnAG prevent 
cell death in cardiomyocytes and endothelial cells (Baldanzi et al., 2002), promote fusion and 
differentiation of C2C12 myoblasts (Filigheddu et al., 2007), induce proliferation and inhibit 
apoptosis in β-pancreatic cells (Granata et al., 2007). In addition, UnAG enhances muscle satellite 
cell activity, activates autophagy and mitophagy, and stimulates insulin sensitivity, thus promoting 
muscle regeneration or preventing skeletal mass loss in different disease models, including hindlimb 
ischemia, high-fat diet-induced diabetes, and chronic kidney disease (Togliatto etl a., Gortan 
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Cappellari et al., 2016; Gortan Cappellari et al., 2017; Reano et al., 2017). As GHSR1a receptor is 
not expressed on cardiomyocytes, skeletal myoblasts and pancreatic, the effects of Ghrelin on these 
cell populations is GHSR1a-independent, proving the existence of an alternative receptor, perhaps a 











Figure 7. Ghrelin acylation by GOAT is necessary for GHSR1a binding. Ghrelin circulates in plasma in two forms: 
acylated and unacylated ghrelin. GOAT-dependent post translational acylation on serine 3 residue of ghrelin is crucial 
to confer biological activity via GHSR1a. UnAG ghrelin does not bind GHSR1a, but shares with AG several biological 
activities independently of GHSR1a, reliant to a yet unidentified receptor (Andrews, 2010).  
 
Ghrelin and skeletal muscle 
The lack of expression of GHSR1a receptor on skeletal muscle means that ghrelin peptides affect 
directly skeletal muscle through the yet unidentified receptor. In particular, it has been demonstrated 
that UnAG impairs catabolic activities induced by the combined treatment with TNF-a and IFN-g in 
cultured C2C12 myotubes (Sheriff S etl al. 2012), and both AG and UnAG protect from 
dexamethasone-induced atrophy (Porporato et al. 2013). 
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Moreover, ghrelin influence regulation of skeletal muscle mass by stimulation of insulin-like growth 
factor 1 (IGF-1) production (Chen et al., 2015). However, independently of GH/IGF- axis activation 
and GHSR1a binding, AG as well as UnAG display a direct antiatrophic activity on skeletal muscles 
in vivo. Indeed, in vivo studies have shown that both ghrelin peptides protect skeletal muscle from 
wasting induced by burning, fasting, and denervation (Sheriff S etl al. 2012; Porporato et al. 2013; 
Wu et al., 2018).  
Cachexia and sarcopenia are two different multifactorial processes phenotypically characterized by 
muscle loss. The evidence of ghrelin dysregulation in both muscle-wasting associated conditions and 
the well-established protective effect of ghrelin peptides from muscle atrophy, encouraged further 
studies about the involvement of ghrelin system both in cachexia and sarcopenia.  
 
Ghrelin in cachexia 
Plasma ghrelin levels raise during fasting or low body mass index (BMI)-associated conditions, such 
as cachexia (Akamizu et al., 2010; Haqq et al., 2003).  
Ghrelin peptide levels are increased in most patients affected by cancer cachexia compared with 
patients without cancer or cancer patients without cachexia (Shimizu et al., 2003; Garcia et al., 2005; 
Mondello et al., 2014). However, despite the increased ghrelin levels, cancer cachectic patients did 
not show increased appetite. During cachexia progression, ghrelin levels could be enhanced as a 
compensatory mechanism in response to weight loss, negative energy balance, reduced appetite, and 
inflammation (Chopin et al., 2012; Garcia et al. 2005, Baatar et al. 2011), suggesting that cachexia 
might lead to a ghrelin resistance status. Nevertheless, this latter condition did not limit ghrelin use 
in therapy, as it has been demonstrated that treatments with high dose of ghrelin or with molecules 
able to potentiate ghrelin signaling ameliorate anorexia symptoms overcoming ghrelin resistance 
(Terawaki et al., 2017; Argilés, 2013). Ghrelin controls mediators involved in the cachectic process 
(Argilés 2013), indeed it is a multi-functional hormone affecting positively a variety of organs 
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impaired during cancer cachexia. Moreover, even if ghrelin activates GH/IGF1 pathway, null or 
inverse association with risk or progression of most cancers has been shown in vivo (Sever et al., 
2016). As a consequence, ghrelin has been considered a worthwhile treatment to counteract cancer 
cachexia-associated muscle wasting (Terawaki et al., 2017; Argilés, 2013), and for this reason AG 
analogues have been designed and tested, leading to good outcomes (Graf and Garcia, 2017; Currow 
et al., 2017).   
 
Ghrelin in sarcopenia  
Endocrine system and metabolic deregulation, which occurs during aging, could contribute to the 
onset of sarcopenia. Elderly subjects display a decline of circulating ghrelin levels (Nass et al., 2014) 
and ghrelin system results dysregulated during aging, as ghrelin-dependent release of growth 
hormone is attenuated. The decline in ghrelin activity can be due to lowered production, decreased 
expression of GHSR1a or alteration in signal transduction (Yin and Zhang, 2016). Otherwise, in 
animal models circulating ghrelin significantly increase with age, probably as a compensatory 
mechanism to the impaired receptor functions observed in aged animals (Kappeler et al., 2004; 
Akimoto et al., 2012; Sun et al., 2007). Ghrelin system impairment plays a role in aging-related 
metabolic alteration, since it is involved in food intake reduction (Akimoto et al., 2012) impaired 
thermogenesis (Lin et al., 2011; Lin et al., 2014), alteration of glucose, lipid and immune system 
homeostasis (Reed et al., 2008; Nesic et al., 2013; Dixit et al., 2007; Dixit et al., 2009; Youm et al., 
2009). Moreover, the hypoghrelinemic status in humans might also participate to sarcopenia 
development by facilitating the progression of muscle wasting and limiting skeletal muscle 
regeneration. Indeed, ghrelin stimulates myoblast fusion and differentiation, exerts a direct anti-
atrophic activity, and promotes skeletal muscle regeneration (Filigheddu et al., 2007; Porporato et al., 
2013; Reano et al., 2017).  Overall, these evidence strongly suggest that ghrelin may be a therapeutic 
strategy to counteract sarcopenia.   
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Introduction to the paper “Both ghrelin deletion and unacylated 
ghrelin overexpression preserve muscles in aging mice” 
 
Agosti E, De Feudis M, Angelino E, Belli R, Alves Teixeira M, Zaggia I, Tamiso E, Raiteri T, 
Scircoli A, Ronzoni FL, Muscaritoli M, Graziani A, Prodam F, Sampaolesi M, Costelli P, Ferraro 
E, Reano S, Filigheddu N. 
Aging – under review
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Low ghrelin circulating levels have been observed in elderly subjects, and this condition could 
participate in the establishment of sarcopenia by facilitating the progression of muscle atrophy and 
limiting skeletal muscle regeneration capability.  
Administration of AG analogues has been explored in several conditions characterized by muscle 
wasting, including cancer cachexia and aging (Garcia J et al., 2015; Currow et al., 2017; White et l., 
2009; Adunsky et al., 2011). However, in sarcopenia, conversely to the beneficial effects observed in 
cancer cachexia, the administration of AG display scarce effect on skeletal muscle accompanied by 
an increase in adiposity that might worsen age-related insulin resistance and metabolic dysfunction. 
Since AG could have adverse metabolic effects potentially worsening sarcopenic status in the elderly, 
we explored the potentiality of UnAG in protecting from age-associated muscle wasting in animal 
models. We showed that not only lifelong overexpression of UnAG in mice, but also the deletion of 
ghrelin gene attenuated the age-associated muscle atrophy and functionality decline, as well as 
systemic inflammation. Overall, our findings prompted the design of UnAG mimetics which could 
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Sarcopenia, the decline in muscle mass and functionality during aging, might arise from age-
associated endocrine dysfunction. Ghrelin is a hormone circulating in both acylated (AG) and 
unacylated (UnAG) forms with anti-atrophic activity on skeletal muscle. Here, we show that not only 
lifelong overexpression of UnAG (Tg) in mice, but also the deletion of ghrelin gene (Ghrl KO) 
attenuated the age-associated muscle atrophy and functionality decline, as well as systemic 
inflammation. Yet, the aging of Tg and Ghrl KO mice occurs with different dynamics: while old Tg 
mice seem to preserve the characteristics of young animals, Ghrl KO mice features deteriorate with 
aging. However, young Ghrl KO mice show more favorable traits compared to WT animals that 
result, on the whole, in better performances in aged Ghrl KO animals. Since Ghrl KO mice share 
several features of mice devoid of AG-specific receptor Ghsr-1a, we speculate that, in Ghrl KO mice, 
the major determinant factor of their overall better conditions is the lack of AG-mediated activation 
of Ghsr-1a. Altogether, these data confirmed and expanded some of the previously reported findings 
and advocate for the design of UnAG analogs rather than AG ones to treat sarcopenia. 
 
Introduction 
Sarcopenia, the decline in muscle mass and functionality during aging, often results in poor balance, 
higher risk of falls, fractures, immobilization, loss of independence, and increased morbidity and 
mortality, thus representing a major health issue in elder individuals [1–3]. 
Muscle wasting follows the general decline in trophic hormones or in their ability of eliciting their 
standard cellular response (“resistance”) and the establishment of a chronic mild inflammatory status 
characteristic of aging [4]. 
Ghrelin is a gastric hormone peptide circulating in both acylated (AG) and unacylated (UnAG) forms. 
AG is the endogenous ligand of the growth hormone secretagogue receptor (GHSR-1a), and it is 
involved in metabolic regulation and energetic balance through induction of appetite, food intake, 
and adiposity [5,6]. UnAG does not induce GH release and has no direct effects on food intake, but 
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it shares with AG several biological activities both in vitro and in vivo independently of the expression 
of AG receptor. Indeed, in vivo, both AG and UnAG protect Ghsr KO mice from fasting- and 
denervation-induced skeletal muscle atrophy, thus proving the existence of a yet unidentified receptor 
that mediates the common AG and UnAG biological activities [7]. Consistently, both AG and UnAG 
have direct biological activities in vitro on skeletal muscle, including promotion of myoblast 
differentiation [8], protection from atrophy [7], and stimulation of mitochondrial respiration capacity 
[9]. In addition, UnAG boosts muscle satellite cell activity, activates autophagy and mitophagy, and 
stimulates insulin sensitivity, thus promoting muscle regeneration or preventing skeletal mass loss in 
different disease models, including hindlimb ischemia, high-fat diet-induced diabetes, and chronic 
kidney disease [10–14].  
Similarly to other hormones, in humans, ghrelin levels decrease with aging [15], and the 
hypoghrelinemic state in the elderly could participate in the establishment of sarcopenia by 
facilitating the progression of muscle atrophy and limiting skeletal muscle regeneration capability. In 
mice, on the contrary, it was reported an increase in circulating levels of AG during aging [16], a 
phenomenon that has been proposed to represent a compensatory mechanism to a decline in receptor 
or post-receptor functions [17].  
The role of ghrelin during aging has been recently investigated through the analysis of ghrelin 
knockout mice, and, surprisingly, it has emerged that ghrelin deletion prevents age-associated 
development of obesity and attenuates the decline in muscle strength and endurance seen with aging 
[18]. Nevertheless, the treatment of old WT mice with AG partially restored muscle performance 
while increasing food intake and body weight, especially fat mass [18]. Since an increase in obesity, 
a side effect of AG, in elderly subjects could worsen sarcopenia [19], inducing insulin resistance and 
diabetes [20], and mediating age-associated adipose tissue inflammation [21], here we explored the 
potentiality of UnAG in protecting from age-associated muscle wasting avoiding the potential adverse 
metabolic effects of AG. In addition, we expanded the previously reported characterization of ghrelin 
knockout mice during aging, especially focusing on the differences between young and aged muscles.  
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Results 
Body weight, body composition, and food intake in young and old WT, Tg, and Ghrl KO mice. 
To address whether ghrelin levels during aging affect sarcopenia development, we examined young 
(3-month-old) and old (24-month-old) Myh6/Ghrl transgenic mice characterized by high levels of 
circulating UnAG, up to 100 times more than WT animals (Tg; [7,13]), their WT littermates, and 
ghrelin knockout (Ghrl KO; [22]) mice, lacking all the gene-derived peptides. 
Beside the already demonstrated age-related increase of AG [16], in WT mice, we also observed a 
rise in the circulating levels of UnAG (Supplementary Fig. 1), a phenomenon that could represent a 
compensatory mechanism to age-induced ghrelin resistance. 
We observed a general increase in BMI and food intake for both WT and Tg mice during aging, while 
Ghrl KO mice exhibited a higher BMI and food intake already at 3 months of age without a further 
increase during aging (Fig. 1A and B). Despite the increase of BMI, at 24 months of age, a drop of 
both epididymal fat and skeletal muscles were observed (Fig. 1C and D, and Supplementary Fig. 2), 
indicating a general loss of fat mass and sarcopenic status in all genotypes and suggesting that other 
factors contribute to the observed increase in BMI of WT and Tg animals. 
 
Muscle and cognitive performance in young and old WT, Tg, and Ghrl KO mice. 
To assess the effect of altered ghrelin levels during aging on muscle functionality, we measured the 
performances of young and old WT, Tg, and Ghrl KO mice using the hanging wire test. This test 
allows determining muscle function and coordination by counting the times a mouse falls or reaches 
one of the sides of the wire and the tension that the animal develops for maintaining itself on the wire, 
against gravity, by measuring the longest suspension time. Surprisingly, Ghrl KO mice outclassed 
both WT and Tg mice, at both ages in the “falls and reach” score (Fig. 2A). On the other hand, Tg 
mice performances were barely distinguishable from those of their WT littermates, both in young and 
old animals. However, the latency times between two successive falls, recorded in the same functional 
test, showed that Tg mice were able to maintain a good muscle condition during aging and confirmed 
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the better performance of Ghrl KO mice at both ages (Fig. 2B). In general, both WT and Ghrl KO 
mice showed a decrease in muscle performance during aging, while, apparently, Tg mice 
performances were preserved. 
Since the score on the hanging wire test could be affected by cognitive performance and stress 
susceptibility, we assessed if cognitive capability and anxiety/depression of mice were different 
among the strains. At 3 months of age, Ghrl KO mice undergoing the object recognition test obtained 
a higher discrimination index than WT and Tg (Fig. 2C). However, at 24 months of age, while no 
significant changes were observed in the discrimination index of WT and Tg mice, that of Ghrl KO 
mice dropped to a level similar to those of WT mice. The tail suspension test, with the time spent 
immobile representing a measure of anguish, showed no differences in the immobility time of young 
mice (Fig. 2D). During aging, both WT and Tg mice showed a mild increase in the immobility time 
compared to young mice, suggesting the development of depression-like behavior. On the contrary, 
Ghrl KO mice shoved substantial preservation of this parameter during aging.  
 
Skeletal muscle atrophy during aging in WT, Tg, and Ghrl KO mice  
Despite the lack of significant differences in the weight of muscles among the three genotypes and 
the general decrease in muscle mass in aged mice (Fig. 1D and Supplementary Fig. 2), a closer 
examination of muscles revealed differences in the expression of Atrogin-1 (Fbxo32), a marker and 
a mediator of muscle atrophy, during aging [23]. The age-dependent increase of Atrogin-1 mRNA 
expressions was remarkable in gastrocnemii of WT and Tg mice and was milder in Ghrl KO mice 
(Fig. 3A), although it should be considered that Atrogin-1 mRNA levels were basally lower in young 
Ghrl KO mice compared to the other genotypes. This was also true in tibialis anterior (TA) muscles, 
where Atrogin-1 was significantly increased during aging only in Ghrl KO mice, reaching the values 
of young WT and Tg animals. Conversely, the increase of Atrogin-1 during aging was not significant 
in WT and absent in Tg animals. Nevertheless, analyzing the fiber cross-sectional area distributions 
of gastrocnemius (GAS) muscles from young adult and old WT mice, it was evident a clear shift 
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toward smaller areas in the latter (supplementary Fig. 3). Since the muscles of young Tg and KO 
mice, in unstimulated conditions, do not differ from those of WT animals [13,22], the shift towards 
larger areas in old Tg and Ghrl KO muscles compared to WT (Fig. 3B), indicate that both high levels 
of circulating UnAG and the lack of ghrelin peptides protect against muscle mass loss during aging.  
 
Muscle fiber types and metabolism in old WT, Tg, and Ghrl KO mice 
Muscles are more susceptible/resistant to atrophy also depending on their fiber type composition, 
being glycolytic fibers more prone to undergo mass loss compared to the oxidative ones [24]; 
therefore, we assessed if high levels of UnAG or the lack of ghrelin peptides could affect muscle 
metabolism. Succinate-dehydrogenase (SDH) staining revealed that oxidative ability, i.e., the activity 
of complex II of the electron transport chain, decreases with aging both in WT and Ghrl KO mice, 
whereas it was maintained in Tg (Fig. 4A-B), suggesting that UnAG stimulates an oxidative 
metabolism, counteracting the age-associated shift from oxidative to glycolytic metabolism.  
Since aging muscles display mitochondrial dysfunction [25], we assessed the expression levels of 
mitochondria and oxidative metabolism markers such as mitochondrial transcription factor A 
(TFAM), ATP-synthase -subunit ( -ATPase), SDH subunit-A (SDHA) and peroxisome 
proliferator-activated receptor gamma (PPAR ). In line with the results reported in Fig. 4A-B, we 
observed an up-regulation of SDHA in old Tg mice compared to WT (Fig. 4C-D). In addition, old Tg 
mice showed an increase in PPAR  with a more oxidative metabolism induced by UnAG. On the 
other hand, -ATPase and PPAR -coactivator-1-alpha (PGC1 ), a master regulator of 
mitochondrial biogenesis, did not show different expression levels among the three genotypes. Yet, 
Ghrl KO mice showed an up-regulation of TFAM, another marker of mitochondrial biogenesis.   
 
Inflammation markers in old WT, Tg, and Ghrl KO mice 
With age, the spleen undergoes enlargement and disorganization of its architecture that can lead to 
age-related decline of immune function and chronic inflammation, that, in turn, could contribute to 
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the decrease in muscle mass and functionality [26–28]. All three genotypes showed a significant 
increase of spleen weight with age, although to a lesser extent in Ghrl KO mice (Fig. 5A). Adipose 
tissue as well contributes to the establishment of age-associated systemic inflammation, as it becomes 
dysfunctional with age, increasing the production of pro-inflammatory cytokines while decreasing 
the anti-inflammatory ones [29]. TNF  mRNA levels in epididymal fat equally increased during 
aging in all the genotypes, but to a lesser extent in Tg and Ghrl KO mice (Fig. 5B), confirming the 
low-grade systemic inflammation in these mice. The impact of ghrelin peptide levels on age-related 
systemic inflammation was explored through an antibody-spotted array directed against several 
circulating markers of inflammation (Fig. 5C and Supplementary Fig. 4). As expected, old WT mice 
showed a general increase of pro-inflammatory markers and a concomitant decrease of the anti-
inflammatory ones compared to young mice (reference line in Fig. 5C). The levels of some of these 
markers, such as SDF1 , eotaxin-1 (CCL11), I-309 (CCL1), leptin, M-CSF, and IL-12p70, were 
lower in both old Tg and Ghrl KO mice compared to old WT. Conversely, the anti-inflammatory 
soluble TNF-R1 was increased in both Tg and Ghrl KO mice. Old Tg mice distinguished themselves 
from WT and Ghrl KO for the high levels of BLC (CXCL13), while characteristics of Ghrl KO mice 
were a lower level of IL-13 and higher levels of IL-12. 
 
Changes in brown adipose tissue in old WT, Tg, and Ghrl KO mice 
Brown adipose tissue (BAT) controls energy expenditure and metabolism through uncoupling protein 
(UCP)1-mediated heat production, thus increasing energy expenditure, reducing adiposity, and 
lowering insulin resistance. Therefore, it has been proposed that age-associated decrease in BAT 
depots and functionality contributes to the metabolic deregulation characteristic of aging [30], which 
may lead to thermogenic impairment and age-associated obesity [16].  We observed a decrease in 
BAT depots in all the strains studied (Fig. 6A). However, UCP-1 expression, an indicator of BAT 
function, was maintained in old Tg mice, and even increased in Ghrl KO mice (Fig. 6B), thus likely 
maintaining proper metabolism homeostasis.  
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Discussion 
The decline in muscle mass, functionality, and physical performance distinctive of aging can be 
ascribed, at least in part, to age-associated endocrine and metabolic dysfunction. Among the 
dysregulated hormones, in humans, it has been observed reduced circulating levels of ghrelin and 
decreased expression on the cell surface of its receptor GHSR-1a [17] that may contribute to 
sarcopenia by facilitating the progression of muscle atrophy and limiting skeletal muscle regeneration 
capability. In mice, on the contrary, it was reported an increase in circulating levels of AG during 
aging and no changes in UnAG [16]. However, together with the age-related increase of AG, we also 
observed a rise in the circulating levels of UnAG (Supplementary Fig. 1), a phenomenon that could 
represent a compensatory mechanism to a decline in receptor or post-receptor functions [17]. The 
age-related increase in AG and UnAG levels may be part of an adaptive response to a negative energy 
balance and suggests that these peptides could be involved in the aging process for the many activities 
that characterize each or both forms of ghrelin peptide, including the protection from muscle wasting 
(AG and UnAG; [7]). Muscle atrophy is indeed one of the main degenerative processes involved in 
sarcopenia and, for the above-mentioned anti-atrophic activity of AG and UnAG, it was reasonable 
to expect that high circulating levels of UnAG, as in the Tg mice used in this study, would result in 
less sarcopenia by protecting from muscle wasting. This was actually the case, being Tg muscles 
partially resistant to the loss of muscle mass and functionality during aging (Fig. 2B, and Fig. 3).  
On the contrary, the finding that old Ghrl KO mice were atrophy-resistant, featuring both lower levels 
of Atrogin-1 and larger myofiber areas than WT mice (Fig. 3), was less expected, as we have formerly 
demonstrated that, upon a traumatic event, muscle regeneration in Ghrl KO mice is reduced, due to 
an impaired satellite cell self-renewal activity [22]. Also, old Ghrl KO mice are more susceptible to 
fasting-induced muscle atrophy likely because of an altered mitochondrial function [9]. Nevertheless, 
most of our findings on aged Ghrl KO mice are in accordance with the previous demonstration that 
ghrelin gene deletion results in the prevention of the age-associated decline in muscle strength and 
endurance [18]. In particular, Ghrl KO muscles showed enhanced physical performance compared to 
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the WT (Fig. 2B). Yet, we also obtained some different results compared with the previously 
published ones. For a start, we observed a loss of muscle weight with aging in both WT and Ghrl KO 
mice (Fig. 1D and Supplementary Fig. 2). However, the weighing of freshly isolated muscles is a 
rough evaluation of muscle mass, and, indeed, a more accurate assessment of muscles uncovered 
relevant differences between WT and Ghrl KO mice. The lack of ghrelin affected muscle cross-
sectional areas, with old Ghrl KO muscles displaying a reduced number of the smallest myofibers in 
CSA distribution compared to WT and expressing less Atrogin-1, which was lower in young Ghrl 
KO than in WT as well (Fig. 3). More importantly, the discrepancies between our data and some of 
the previously published ones, e.g., BMI/body weight and food intake of Ghrl KO mice (Fig. 1 
compared to the data shown in [18]) depend on the different age ranges used, i.e., 3-month-old for 
young animals instead of 6- to 9-month-old young adults. Indeed, the differences observed in BMI in 
young mice disappear at the age of 6 months (Supplementary Fig. 5).   
The changes in muscle mass occurring during aging may arise from the age-related dysregulation of 
the immune system that leads to progressive systemic inflammation, with a general increase in 
circulating pro-inflammatory cytokines, which can affect muscle homeostasis. Actually, old WT mice 
exhibited higher spleen dimension and increased levels of TNF-  expression in epidydimal adipose 
tissue and of plasmatic pro-inflammatory markers compared to young animals, confirming the 
existence of low-grade systemic inflammation (Fig. 5 A-C). Based on the vast amount of the anti-
inflammatory activities of ghrelin peptides [31], a worsening of the inflammatory status in Ghrl KO 
mice was plausible. However, Ghrl KO mice displayed reduced systemic inflammation and less 
inflamed adipose tissue (Fig. 5B and C), a phenotype strongly reminiscent of that of Ghsr KO mice 
[32], in which the ablation of AG receptor promotes a shift in macrophages toward the anti-
inflammatory M2 status and reduced macrophage infiltration and pro‐inflammatory cytokine 
expression in white and brown adipose tissues.  
Also, the pro-inflammatory effects of Ghsr-1a on macrophages profoundly limits lipid mobilization 
and energy expenditure in adipose tissue [21], processes that are highly perturbed during aging [33]. 
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In particular, it was proposed that AG could participate in the age-related impairment of 
thermogenesis –thus contributing to the onset of age-related obesity and insulin resistance– through 
its receptor Ghsr-1a, whose expression in fat increases with aging [32]. Despite the general age-
dependent reduction in brown fat, the higher levels of UCP-1 in Ghrl KO mice suggest an enhanced 
thermogenic activity. Therefore, it is conceivable that ghrelin ablation might shift the metabolic state 
of old mice from obesogenic to thermogenic. However, a specific assessment of energy expenditure 
would be needed to prove this hypothesis. Altogether, these observations strongly suggest that, in 
Ghrl KO mice, one of the major determinant factors of their overall better conditions is the lack of 
AG-mediated activation of Ghsr-1a. Conversely, the lack of UnAG in these mice becomes critical 
under stressful conditions, such as starvation or acute muscle injury, impacting on the physiological 
homeostasis [9,22]. 
Of note, the feeding behavior of Ghrl KO mice was different from what previously reported [18,34], 
as we observed higher food consumption not only during aging in WT but, more curiously, also in 
young Ghrl KO mice (Fig. 1B). The BMI seems to reflect the food intake, with young Ghrl KO mice 
showing a higher BMI compared to WT (Fig. 1A). However, the loss in muscle and epidydimal fat 
mass indicates that other tissues contribute to the increase in BMI. Indeed, we observed a remarkable 
increase in spleen (Fig. 5A) and liver weight (data not shown) with aging that could account for the 
BMI values.  
Besides the effects on skeletal muscle, aging also associates often with a gradual cognitive 
impairment and depression that deeply worst elder people quality of life [35]. The role of AG in 
regulating sleep and memory [36] and its anti-depressant activity when administered to stressed mice 
[37] suggest that the impairment of ghrelin signaling during aging could affect cognitive function as 
well. In assessing the behavioral contribution to the physical performance tests, we skimmed the 
surface of this issue and surprisingly found that the lack of ghrelin peptides improved the memory 
capacity of young mice, although this effect was not maintained in old mice (Fig. 2C). Conversely, 
the lack of the ghrelin gene protected against the onset of the aging-dependent depression-like 
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behaviors (Fig. 2D). Altogether, the pattern of cognitive function could have partially affected the 
measure of endurance in the hanging wire test (Fig. 2B), as the cleverness could drive the mice to 
quickly reach the ends of the wire (Fig. 2C), while the anxiety/depression (Fig. 2D) may induce the 
mice to abandon the attempt. Therefore, old WT mice could have performed worse than their young 
counterpart also because of the establishment of age-induced anxiety/depression. On the contrary, 
Ghrl KO mice could have had a starting advantage due to higher cognitive performance in youth. 
Although this parameter declined with age, it reached the level of young WT animals, and the lack of 
anxiety/depression during aging could have resulted in overall better performances both in young and 
old Ghrl KO mice than their WT peers. 
Exogenous administration of AG to overcome a presumed peripherical ghrelin resistance has been 
explored in several contexts characterized by loss of skeletal muscle mass, including cancer cachexia 
[38,39] and aging [18]. However, while in cancer cachexia the administration of AG has a beneficial 
activity on skeletal muscle also by contrasting anorexia and the rapid loss of adipose tissue, in 
sarcopenia the effects on skeletal muscle are limited and accompanied by an increase in adiposity that 
might worsen age-related insulin resistance and metabolic dysfunction. The pro-adipogenic feature 
of AG relies on its acylation and resulting binding to Ghsr-1a [6,40]. Since UnAG does not activate 
this receptor and does not increase fat mass, while protecting the skeletal muscle from several atrophic 
stimuli [41], we investigated the potentiality of this hormone in preventing sarcopenia by monitoring 
the aging of Myh6/Ghrl Tg mice characterized by normal levels of AG but increased levels of UnAG 
[7,13]. Despite both Tg and WT animals display similar tendencies in how BMI, epididymal fat, and 
skeletal muscle weight change with aging (Fig. 1 and Supplementary Fig. 2), higher circulating levels 
of UnAG seem to globally maintain in the long run the structure, performance, and metabolism typical 
of young muscles (Fig. 2 A-B, Fig. 3, and Fig. 4). In particular, old Tg muscles display higher levels 
of mitochondrial protein than WT littermates (Fig. 4D) that likely accounts for the maintenance of 
the oxidative metabolism (Fig. 4A and B) and the overall protection from sarcopenia. This is 
consistent with the ability of UnAG to impair muscle catabolism by mitigating mitochondrial damage 
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[14]. The preserved muscle mass and functionality may be the result of the direct anti-atrophic activity 
of UnAG [7,8], as well as of the reduced age-associated chronic inflammation (Fig. 5B). Although 
old Tg spleen weight did not differ from that of WT (Fig. 5A), old Tg animals were characterized by 
lower levels of inflammatory markers (Fig. 5B), such as SDF-1 , I-309, leptin, M-CSF, IL-12p70, 
and higher levels of soluble TNF-R1 that can act as scavenger for the circulating inflammatory TNF-
 [42]. On the other hand, age-associated IL-12 and IL-13 levels were quite similar to those observed 
in WT animals, possibly reflecting the presence of AG in Tg mice.  
Differently from Ghrl KO mice, the lower systemic inflammation does not associate with increased 
UCP-1 expression (Fig. 6B). However, we imagine that the maintenance during aging of brown fat 
(Fig. 6A), could result in a similar thermogenic, obesity-resistant phenotype. 
In conclusion, we showed that both high circulating levels of UnAG and the lack of ghrelin gene 
prevent the decline of muscle function associated with aging, although with different dynamics. 
Indeed, old Tg mice seem to preserve the characteristics of young animals, while Ghrl KO mice 
features deteriorate with aging. However, young Ghrl KO mice in general show more favorable traits 
compared to WT animals that result, on the whole, in better performances in aged Ghrl KO animals. 
The only exception is the SDH activity (Fig. 4B) that declines with age in both WT and Ghrl KO 
mice, but, differently from the other parameters assessed in this work, young Ghrl KO mice do not 
have the initial advantage of higher SDH activity in youth. On the contrary, similarly to other 
parameters, Tg mice maintain a constant SDH activity, putatively due to higher levels of 
mitochondrial proteins (Fig. 4D). Therefore, we can hypothesize that the maintenance of the oxidative 
metabolism could, at least in part, explain the protection from sarcopenia in Tg mice, while, in Ghrl 
KO mice, the lack of Ghsr-1a-mediated inflammation could play a major role.  The fact that Ghrl KO 
mice are protected from sarcopenia might still appear in contradiction with our previous work 
demonstrating that both AG and UnAG have anti-atrophic activities [7]. However, it should be noted 
that the anti-atrophic effects of AG UnAG were assessed in Ghsr KO mice, i.e., in circumstances in 
which AG was not signaling via Ghsr-1a, but through a yet unidentified receptor. 
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The astonishingly similarity between old Ghrl KO mice and old Ghsr KO mice indeed strongly 
suggests a detrimental role for GHSR-1a in the onset of sarcopenia. We reckon that, in mice, the 
physiological increase of UnAG with aging is not enough to counteract the negative effects of the 
increased AG levels, and that, in humans, the adverse effects of impaired ghrelin signaling in aging 
are mainly due to the decline in UnAG rather than AG. Altogether, these results should encourage 

























Figure 1. Body mass composition and food intake in young and old WT, Tg, and Ghrl KO mice. (A) Body mass 
composition measured as body mass index (BMI) in 3-month old (young) and 24-month old (old) mice. Young mice: 
WT= 4, Tg= 5, Ghrl KO = 4; old mice: WT= 13, Tg= 14, Ghrl-/-= 11. (B) Total food intake consumed by mice in 12 days 
with ad libitum access to standard chow diet. Young mice: WT= 5, Tg= 5, Ghrl KO = 5); old mice: WT= 7, Tg= 7, Ghrl 
KO = 7. (C) Epidydimal fat mass normalized to anus-nose length and (D) gastrocnemius weight normalized to the tibial 
length. Young mice: WT= 4, Tg= 5, Ghrl KO = 4; old mice: WT= 13, Tg= 14, Ghrl KO = 11. Data in bar graph are 
presented as mean ± SEM. For each box plot, the lower and up boundaries denote the 25th and the 75th percentile of each 
data set, respectively, the horizontal line represents the median, and the whiskers represent the min and max of values. 
































































































Figure 2. Muscle functionality and behavior in young and old WT, Tg, and Ghrl KO mice. (A) Average score trend 
in hanging wire test of in 3-month old (young) and 24-month old (old) WT, Tg, and Ghrl KO mice and (B) average 
latency-to-fall in the same test. Young mice: WT= 21, Tg= 21, Ghrl KO= 27; old mice: WT= 9, Tg= 16, Ghrl KO= 7. 
*p<0.05 and **p<0.01 vs WT. (C) Memory was evaluated through the object recognition test and expressed as a 
discrimination index between a familiar and a novel object (seconds on novel – seconds on familiar)/(seconds on novel + 
seconds on familiar). (D) Anxiety was assessed as the time spent immobile after a minute of tail suspension. Young mice: 
WT= 5, Tg= 5, Ghrl KO= 5; old mice: WT= 6, Tg= 7, Ghrl KO= 6. For each box plot, the lower and up boundaries denote 
the 25th and the 75th percentile of each data set, respectively, the horizontal line represents the median, and the whiskers 
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Figure 3. Ghrelin peptides effects on sarcopenia-dependent atrophy. (A) Atrogin-1 (Fbxo32) expression in 
gastrocnemius (GAS) and tibialis anterior (TA) of 3-month old (young) and 24-month old (old) mice determined by real-
time RT-PCR. In TA, young mice: WT= 4, Tg= 3, Ghrl KO= 4; old mice: WT= 8, Tg= 9, Ghrl KO= 8. In GAS, young 
mice: WT= 4, Tg= 4, Ghrl KO= 4; old mice: WT= 4, Tg= 3, Ghrl KO= 4. (B) Cross-sectional area (CSA) frequency 
distribution of myofibers in GAS of old WT, Tg, and Ghrl KO mice. WT= 4, Tg= 3, Ghrl KO= 5. The shadowed area of 
the graph represents the section of statistically significant differences among curves. Data are presented as mean ± SEM. 









































































Figure 4. Metabolic shift in TA muscles of WT, Tg, and Ghrl KO mice. (A) Representative images of succinate 
dehydrogenase (SDH) staining (scale bars: 200 μm) representing the oxidative capacity of TA muscles of 3-month old 
(young) and 24-month old (old) mice. (B) Quantification of SDH-positive fibers in TA muscle presented as the percentage 

















































































































3, Ghrl KO= 5. (C) Representative Western blots images and (D) protein densitometry quantification for mitochondrial 
transcription factor A (TFAM), ATP-synthase β-subunit (β-ATPase), succinate-dehydrogenase complex subunit-A 
(SDHA), peroxisome proliferator-activated receptor gamma (PPARγ), and PPARγ-coactivator-1-α (PGC1α) protein 
levels. Protein levels were probed in gastrocnemii of old mice, WT= 4, Tg= 5, Ghrl KO= 5. Data are presented as mean 





































































































Figure 5. Systemic inflammation in old WT, Tg, and Ghrl KO mice. (A) Spleen weight in 3-month old (young) and 
24-month old (old) mice. Young mice: WT= 4, Tg= 5, Ghrl KO= 4; old mice: WT= 13, Tg= 14, Ghrl KO= 11. (B) TNF-
α (Tnf) expression in epididymal fat of 3-month old (young) and 24-month old (old) WT, Tg, and Ghrl KO mice, 
determined by real-time RT-PCR. Young mice: WT= 3, Tg= 4, Ghrl KO = 4; old mice: WT= 5, Tg= 7, Ghrl KO = 5. (C) 
Serum biomarkers involved in systemic inflammation normalized on the levels in young WT mice (reference line). Young 
mice WT=4; old mice: WT= 4, Tg= 4, Ghrl KO = 4 pulled into two groups. For each box plot, the lower and up boundaries 
denote the 25th and the 75th percentile of each data set, respectively, the horizontal line represents the median, and the 
whiskers represent the min and max of values. Data in bar graph are presented as mean ± SEM (B) and mean ± SD (C). 





Figure 6. Changes in brown adipose tissue in old ghrelin WT, Tg, and Ghrl KO mice. (A)  Brown fat mass normalized 
to anus-nose length. Young mice: WT= 4, Tg= 5, Ghrl KO = 4; old mice: WT= 13, Tg= 14, Ghrl KO = 11. (B) Uncoupling 
protein-1 (Ucp-1) expression in brown fat of young and old WT, Tg, and Ghrl KO mice determined by real-time RT-
PCR. Young mice: WT= 4, Tg= 4, Ghrl KO= 4; old mice: WT= 3, Tg= 4, Ghrl KO= 3. Data in bar graph are presented 
as mean ± SEM. For each box plot, the lower and up boundaries denote the 25th and the 75th percentile of each data set, 
respectively, the horizontal line represents the median, and the whiskers represent the min and max of values. *p<0.05 















































Supplementary figure 1. Muscle weight in young and old WT, Tg, and KO mice. Tibialis anterior (TA) (A), quadriceps 
(QUAD) (B), soleus (SOL) (C), extensor digitorum longus (EDL) (D) weight normalized to tibial length. Young mice: 
WT= 4, Tg= 5, KO = 4; old mice: WT= 13, Tg= 14, KO = 11. Data are presented as mean ± SEM. *p<0.05 and **p<0.01 
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Supplementary figure 3. Increase of AG and UnAG plasmatic levels during aging in WT mice. Plasmatic levels of 
AG (A) and UnAG (B) in 3-, 12-, and 24-month-old mice determined by EIA; 3-month-old mice: N = 5, 12-month-old 
mice N = 8, 24-month-old mice N = 6. *p<0.05 and ** p<0.01 vs. 3-month-old mice. 
 
 
Materials and methods 
 
Animals. Animal experiments were performed according to procedures approved by the Institutional 
Animal Care and Use Committee at the University of Piemonte Orientale. C57BL/6 male mice, 
matched for age and weight, were used for all experiments. C57BL/6 Ghrl-/- (Ghrl KO) and C57BL/6-
Myh6/Ghrl transgenic (Tg) mice were generated as previously described [7,22,43]. WT mice were 
littermates of Tg animals. Ghrl KO strain was kept in homozygosity. Animals were housed in groups 
of 4/6 animals and fed ad libitum with unrestricted access to drinking water. For food intake analysis 
and behavioral tests, mice were single-caged for the acclimation plus experimental periods.  The 
light/dark cycle in the room consisted of 12/12 h with artificial light. The numbers of mice ranged 
from 3 to 27 per experiment. BMI was calculated as animal weight/(nose-to-anus length)2. AG and 
UnAG plasmatic levels were measured by EIA kits (SPIbio Bertin Pharma). Mice were killed through 
cervical dislocation, and tissues used for the study immediately excised, weighted, and processed or 
stored for further analysis.  
 






















Hanging wire test. A wire-hanging test was employed to assess whole-body muscle strength and 
endurance. The test was performed as previously described [13]. Briefly, mice were subjected to 180 
sec hanging test, during which “falling” and “reaching” scores were recorded. When a mouse fell or 
reached one of the sides of the wire, the “falling” score or “reaching” score was diminished or 
increased by 1, respectively. A Kaplan-Meier-like curve was created afterward. Moreover, the longest 
time between two falls was taken as the latency-to-fall value. 
 
Object recognition test. Recognition memory was measured using various objects of different sizes 
and materials, as previously described [44]. Briefly, mice were separated in single cages 10 days 
before the test. The task started with a familiarization trial (day 1) in which two identical objects were 
presented to the animals, followed by the test trial (day 2), where one familiar object was substituted 
with a novel one. In detail, in day 1, mice were left with two identical objects (familiarization phase). 
Exploration was recorded for 10 min by an investigator blinded to the strain assessed. Sniffing, 
touching, and stretching the head toward the object at a distance  2 cm were scored as object 
investigation. In day 2 mice were again left in the same cage containing two objects: one identical to 
one of the objects presented during the familiarization phase (familiar object), and a new, different 
one (novel object), and the time spent exploring the two objects was recorded for 10 min. Memory 
was expressed as a discrimination index calculated as follows: (seconds on novel–seconds on 
familiar)/(seconds on novel + seconds on familiar). Animals with memory impairment spend lesser 
investigating time with the novel object, thus giving a lower discrimination index. 
 
Tail suspension test. Mice anxiety/depression was measured as previously described [45]. Briefly, 
mice were individually suspended in the air by tape attached to a shelf (50 cm height) for 6 min. Trials 
were video‐recorded, and a blinded experimenter scored the time during which mice remained 
immobile as a measure of depressive‐like behavior. A small cylindrical tube was slipped over the 
mouse tail to prevent climbing motion and to escape. 
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Histological analysis. Muscles were excised, weighted, mounted in Killik embedding medium (Bio-
optica), frozen in liquid-nitrogen-cooled isopentane, and stored at -80 °C. Transverse muscle sections 
(7 µm) were cryosectioned from the middle part of each muscle. Myofiber areas were determined by 
immunofluorescence with anti-laminin (1:200; Dako). Slices were fixed in 4% PFA for 20 min, 
washed, permeabilized with 0.2% Triton X-100 in 1% BSA for 15 min, and blocked with 4% BSA 
for 30 min. One hour of incubation with primary antibodies was followed by 45 min of secondary 
antibody (Alexa Fluor 488-anti-rabbit; Thermo Fisher Scientific) at RT. DAPI was incubated for 5 
min at RT to visualize nuclei. SDH staining was performed to reveal the oxidative fibers within a 
muscle. Frozen transverse TA muscles were incubated in a working solution (SUCCINIC 
DEHYDROGENASE Stain Lyophilized, Bio-optica) for 45 minutes at 37°C. The sections were then 
rinsed in distilled water, fixed in 4% PFA for 10 minutes, placed in 15% ethanol for 10 minutes, and, 
finally, mounted with aqueous mounting medium. Images of whole muscle sections were acquired 
with the slide scanner Pannoramic Midi 1.14 (3D Histech) and cross-sectional areas (CSA) of fibers 
or SDH staining quantified with ImageJ software (v1.49o).  
 
Gene expression analysis. Total RNA from muscles was extracted by RNAzol (Sigma-Aldrich). 
RNA was retro-transcribed with High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific), and real-time PCR was performed with the StepOnePlus Real-Time PCR System (Thermo 
Fisher Scientific) using the following TaqMan assays: Mm00499518_m1 (Fbxo32, Atrogin-
1/MAFbx), Mm01244861_m1 (Ucp1), Mm00443258_m1 (Tnf), and Mm00506384_m1 (Ppif).  
 
Western Blotting. Tissue samples from gastrocnemii were homogenized by using GentleMACS 
Dissociator (Miltenyi Biotec) and lysed in ice-cold RIPA Buffer (50 mM Tris/HCL, pH= 8.0; 1% 
Triton X-100; 150mM NaCl; 0.5% sodium deoxycholate; 0.1% SDS) supplemented with a protease 
inhibitor cocktail (Roche) and a phosphatase inhibitor cocktail (Sigma-Aldrich). A clear supernatant 
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was obtained by centrifugation of lysates at 13,000 g for 20 min at 4°C. Protein concentration in the 
supernatant was determined by Bradford protein assay (Bio-Rad). Aliquots of total cell lysates (20 
mg) were then separated by SDS-PAGE by using Miniprotean precast gels (BioRad), and proteins 
were transferred to nitrocellulose membranes (BioRad). 
Membranes were blocked  1h at RT with 5% non-fat milk in Tris-buffered saline with 0.05% Tween 
20 and then probed by using the following antibodies directed against PGC1α (AB3242; Millipore), 
β chain-ATP Synthase (MAB3494; Millipore), PPARγ (sc-7273; Santa Cruz Biotechnology), SDH 
(sc-377302; Santa Cruz Biotechnology), TFAM (sc-23588; Santa Cruz Biotechnology), GAPDH 
(G8795; Sigma-Aldrich). 
The appropriate secondary horseradish peroxidase-conjugated antibodies from Jackson 
Immunoresearch were used in 5% not-fat- milk (blocking solution) for 1 h at room temperature.  
Immunoreactive bands were visualized by Clarity Western ECL Substrate (Biorad). Equal loading of 
samples was confirmed by GAPDH (G8795; Sigma-Aldrich) normalized and quantified by 
densitometry by ImageJ Software.  
 
Mouse Inflammation Antibody Array. Serum cytokines and biomarkers of systemic inflammation 
were detected using the Mouse Inflammation Antibody Array C1 (RayBiotech, Norcross, Georgia, 
USA) according to manufacturer instructions. 
 
Statistical analysis. All data were expressed as mean ± SEM or mean ± SD, when appropriate, 
absolute values, or percentages. Outliers in the measurements were identified by mean of the 
interquartile range (IQR), as either below Q1 − 1.5 IQR or above Q3 + 1.5 IQR, and excluded from 
the analysis. The variation between groups was compared by using nonparametric Wilcoxon, Mann-
Whitney U, or χ2 tests, as appropriate. Statistical significance was assumed for p<0.05. The statistical 
analysis was performed with IBM SPSS Statistics for Windows version 25.0. The * symbol indicates 
a statistically significant difference between old and young animals, for any genotype group; the § 
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symbol identifies a statistically significant difference between WT animals and either Tg or Ghrl KO 




AG   acylated ghrelin 
BAT  brown adipose tissue 
-ATPase ATP-synthase beta-subunit 
BLC  B lymphocyte chemoattractant (CXCL13) 
BMI  body mass index 
BSA  bovine serum albumin 
CCL11 C-C motif chemokine ligand 11 (eotaxin-1) 
CCL1  C-C motif chemokine ligand 1 (I-309) 
CSA  cross-sectional area 
CXCL13  C-X-C motif chemokine ligand 13 (BLC) 
DAPI  4′,6-diamidino-2-phenylindole 
EDL  extensor digitorum longus 
Fbxo32  F-Box Protein 32 (Atrogin-1) 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GAS  gastrocnemius 
GH  growth hormone 
Ghrl  ghrelin (gene) 
Ghsr  growth hormone secretagogue receptor (gene) 
GHSR-1a growth hormone secretagogue receptor type 1a 
IL-13  interleukin-13 
IL-12  interleukin-12 
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IL-12p70 interleukin-12 70 kDa light chain 
KO  knock-out 
M-CSF  macrophage colony-stimulating factor 
Myh6  myosin heavy chain 6 (gene) 
PGC1   PPAR -coactivator-1-alpha 
PFA  paraformaldehyde 
PPAR   peroxisome proliferator-activated receptor gamma 
Ppif   peptidyl-prolyl cis-trans isomerase, mitochondrial 
QUAD quadriceps 
SDF1   stromal cell-derived factor-1-alpha 
SDH  succinate dehydrogenase 
SDHA  succinate dehydrogenase complex flavoprotein subunit A 
SOL  soleus 
TA  tibialis anterior 
TFAM  mitochondrial transcription factor A 
TNFα  tumor necrosis factor alpha 
TNF-R1  tumor necrosis factor receptor 1 
Tg  transgenic 
UCP1  Uncoupling Protein 1 
UnAG  unacylated ghrelin 
WT  wild type 
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Abstract
Purpose Muscle regeneration depends on satellite cells (SCs), quiescent precursors that, in consequence of injury or
pathological states such as muscular dystrophies, activate, proliferate, and differentiate to repair the damaged tissue. A subset
of SCs undergoes self-renewal, thus preserving the SC pool and its regenerative potential. The peptides produced by the
ghrelin gene, i.e., acylated ghrelin (AG), unacylated ghrelin (UnAG), and obestatin (Ob), affect skeletal muscle biology in
several ways, not always with overlapping effects. In particular, UnAG and Ob promote SC self-renewal and myoblast
differentiation, thus fostering muscle regeneration.
Methods To delineate the endogenous contribution of preproghrelin in muscle regeneration, we evaluated the repair process
in Ghrl−/− mice upon CTX-induced injury.
Results Although muscles from Ghrl−/− mice do not visibly differ from WT muscles in term of weight, structure, and SCs
content, muscle regeneration after CTX-induced injury is impaired in Ghrl−/− mice, indicating that ghrelin-derived peptides
actively participate in muscle repair. Remarkably, the lack of ghrelin gene impacts SC self-renewal during regeneration.
Conclusions Although we cannot discern the specific Ghrl-derived peptide responsible for such activities, these data indicate
that Ghrl contributes to a proper muscle regeneration.
Keywords Ghrelin knockout ● Skeletal muscle regeneration ● Satellite cells ● Self-renewal
Introduction
Skeletal muscle is a plastic tissue that regenerates upon
injury through the activation, expansion, and differentiation
of satellite cells (SCs), myogenic precursors characterized
by the expression of the transcriptional factor Pax7 [1].
Muscle damage induces a local release of several factors
that activate SCs, eventually leading to repair of the injured
muscle. Ghrl and preproghrelin are induced by injury [2, 3],
and both unacylated ghrelin (UnAG) and obestatin (Ob),
two products of the ghrelin gene, are among the factors
participating in muscle regeneration, as they increase SC
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activity [3, 4]. Also, their exogenous administration in vivo
—via injection, electroporation, or AAV-mediated delivery
—enhances muscle regeneration in several models of
muscle injury, such as cardiotoxin (CTX)-induced or freeze-
induced injury and hindlimb ischemia [4–6]. Consistently,
muscle regeneration after CTX injury improves also in
transgenic mice characterized by high levels of circulating
UnAG [3].
Along with UnAG and Ob, also acylated ghrelin (AG)
acts on muscle or muscle-derived cells. In particular, both
AG and UnAG promote murine C2C12 myoblast differ-
entiation [7], and Ob has a similar effect on human myo-
blasts [8]. Both UnAG and Ob foster skeletal muscle
regeneration [2–6], and both AG and UnAG protect muscle
from doxorubicin-induced apoptosis [9] and from wasting
in numerous experimental models, such as burn injury [10,
11]; fasting and denervation [12], kidney disease-associated
cachexia [13, 14], and, in vitro, on C2C12 myotubes treated
with dexamethasone or co-cultured with CT26 colon car-
cinoma cells [12, 15]. Several studies evaluated the pro-
tective activity of AG alone and demonstrated its efficacy in
protecting from hindlimb suspension- or angiotensin II-
induced atrophy [16, 17], and from cancer cachexia [18,
19]. Although most of the reported activities of AG and
UnAG in muscle-derived cells—both skeletal and cardiac—
are overlapping, their effects on reactive oxygen species
(ROS) production diverge, being UnAG the only peptide
able to inhibit ROS accumulation [5, 6, 20]. Relevantly,
UnAG, but not AG, induces skeletal muscle regeneration
upon ischemia-induced injury [5].
Here we aim at establishing the impact of endogenous
ghrelin in muscle regeneration using preproghrelin-deficient




C57BL/6 male mice, matched for age and weight, were
used for all experiments. C57BL/6 Ghrl−/− mice were
generated as previously described [21]. Animals were fed
ad libitum and had unrestricted access to drinking water.
The light/dark cycle in the room consisted of 12/12 h with
artificial light. Three mice had been estimated sufficient to
detect 1 SD unit with 80% power and a significance level of
95% at Student’s T-test in CSA frequency distribution
experiments, according to previously published data (Por-
porato 2013). Five mice had been estimated sufficient to
detect differences in Pax7+/BrdU+ cells according to the
same model and previous data (Reano 2017). The number
of mice was calculated with the program by R.V. Lenth
(www.stat.uiowa.edu/~rlenth/Power/index.html). The
investigators conducting the experiments were blind to the
experimental group assessed. The investigators quantifying
the experimental outcomes were maintained blinded to the
animal group or intervention. Finally, the statistic evalua-
tion of the experimental data was performed by another
investigator not directly involved in data collection and
parameter measurement.
CTX-induced muscle regeneration
Experiments on muscle regeneration were conducted on
adult male C57BL/6 and C57BL/6 Ghrl−/− mice matched
for age and weight. CTX from Naja mossambica mos-
sambica (Latoxan) was dissolved in sterile saline to a final
concentration of 10 μM. Mice were anesthetized by iso-
fluorane inhalation and hindlimbs were shaved and cleaned
with alcohol. TA muscles were injected with 45 μl of CTX
with a 30-gauge needle, with 15 microinjections of 3 μl
CTX each in the mid-belly of the muscle to induce a
homogeneous damage [3]. The TA muscles of the con-
tralateral hindlimbs were injected with saline. After injec-
tion, animals were kept under a warming lamp until
recovery.
For the experiments assessing SC self-renewal during
muscle regeneration, immediately after each CTX admin-
istration, a single intraperitoneal injection of 5-bromo-2′-
deoxyuridine (BrdU) (6 μg/g mouse) was given, followed
by BrdU administered ad libitum in drinking water (2.5 mg/
ml) for 17 days.
Histological analysis
Muscles were trimmed of tendons and adhering non-muscle
tissue, mounted in Killik embedding medium (Bio-optica),
frozen in liquid-nitrogen-cooled isopentane, and stored at
−80 °C. Transverse muscle sections (7 µm) were cryosec-
tioned from the mid-belly of each muscle. Sections were
stained with hematoxylin/eosin to reveal general muscle
architecture. Images of whole muscle sections were
acquired with the slide scanner Pannoramic Midi 1.14 (3D
Histech) and cross-sectional areas (CSA) of centronucleated
fibers quantified with ImageJ software (v1.49o). Muscle
collagen content was assessed with Masson trichromic
staining.
Immunofluorescence
For Pax7 and BrdU detection, tissue sections were fixed in
4% PFA for 20 min, washed, permeabilized with cold
methanol for 6 min, and then antigen-retrieved with sodium
citrate (10 mM, 0.05% Tween in PBS) at 95 °C for 30 min.
For blocking the unspecific binding sites, slices were
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incubated in 4% BSA for 2 h at RT and then with M.O.M.
blocking reagent (Vector) for 1 h at RT. Sections were
stained with an anti-Pax7 antibody (1:100; Developmental
Studies Hybridoma Bank) and with anti-BrdU antibody
(1:300; Biorad) overnight at 4 °C. After washing, sections
were incubated with the appropriate Alexa Fluor Dyes-
conjugated secondary antibody (488-anti-mouse/anti-rabbit
or 568-anti-rabbit; Thermo Fisher Scientific) for 1 h at RT.
DAPI was incubated for 5 min.
For immunofluorescence with anti-laminin (1:200;
Dako), after fixing, slices were permeabilized with 0.2%
Triton X-100 in 1% BSA for 15 min and blocked with 4%
BSA for 30 min. One hour of incubation with primary
antibodies was followed by 45 min of secondary antibody
incubation at RT.
Images were acquired using the slide scanner Pannora-
mic Midi Scanner 1.14 (3D Histech) and quantified with
Pannoramic viewer software or ImageJ v1.49o software.
Statistical analysis
All data were expressed as mean ± SEM, absolute values, or
percentages. For continuous variables, the variation
between groups was compared by means of nonparametric
Wilcoxon and Mann-Whitney U tests, as appropriate. When
analyzing experiments acquired with different instruments,
ANCOVA analysis was used to determine differences
between groups by using the instrument as a covariate.
Multiple logistic regression was used for trends. Statistical
significance was assumed for p < 0.05. The statistical ana-
lysis was performed with SPSS for Windows version 17.0
(SPSS; Chicago, IL).
Table 1 Phenotypical characterization of Ghrl−/− mice
WT Ghrl−/−
Body weight (g) 30.69 ± 1.26 28.47 ± 0.65
Nose-to-anus length (mm) 93.59 ± 1.70 93.83 ± 0.75
Tibial length (mm) 19.60 ± 0.20 19.68 ± 0.13
Quadriceps weight (mg) 257.15 ±
13.21
244.15 ± 8.38
Gastrocnemius weight (mg) 167.40 ± 9.5 147.11 ±
16.72
Tibialis anterior weight (mg) 51.53 ± 2.62 51.80 ± 1.29
Extensor digitorum longus weight
(mg)
10.59 ± 1.28 12.42 ± 0.45
Soleus weight (mg) 9.23 ± 0.49 8.85 ± 0.21
Heart weight (mg) 164.58 ±
11.68
138.30 ± 7.72
Measurements of the indicated parameters were performed as
described in the Methods section. Data represent means ± S.E.M. (N
= 5 for each group). The variation between groups was assessed by
nonparametric Wilcoxon and Mann-Whitney U tests. No statistically
significant differences were found in the analyzed features
Fig. 1 In not-injured conditions,
the lack of Ghrl gene does not
impact muscle morphology.
Representative images (upper
panels) of laminin IF and DAPI
staining of not-injured TA
muscle sections from WT and
Ghrl−/− mice (scale bar, 100
µm) and myofiber CSA
frequency distribution (lower
panel). Chi-square test was used
to compare distributions. (CSA
mean ± S.E.M. µm2: WT
1941.63 ± 176.54; Ghrl−/−
1970.48 ± 80.92). N= 5 (WT)
and 4 (Ghrl−/−)
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Results
The lack of Ghrl gene impairs muscle regeneration
Ghrelin mRNA is rapidly and transiently induced in the
injured muscle [2, 3], and preproghrelin-derived peptides
UnAG and Ob contribute to the regenerative process [2, 3,
5, 6]. To further gain insight into the role of Ghrl-derived
peptides in skeletal muscle regeneration, we induced injury
in tibialis anterior (TA) muscle of Ghrl−/− mice by CTX
injection. Although macroscopically Ghrl−/− mice did not
show blatant differences in total body and muscle weight
(Table 1), as well as in muscle morphology, number of Pax7
+ SC (data not shown), and fiber CSA distribution (Fig. 1)
compared with wild-type (WT) mice, at day 7 post CTX
injury, regeneration in Ghrl−/− mice was impaired, as evi-
denced by a shift toward smaller CSA of regenerating (i.e.,
centronucleated) fibers (Fig. 2a). This shift was not
accompanied by an increase in the number of smaller fibers
in the regenerating portion of the muscle, as the total
number of regenerating fiber normalized to the damaged
area was alike in Ghrl−/− and WT mice (Fig. 2b). Similarly,
the number of regenerating fibers with ≥2 nuclei was similar
in both Ghrl−/− and WT mice (Fig. 2c), suggesting that the
lack of preproghrelin does not negatively impact on myo-
blast fusion during regeneration. The defect in regeneration
observed in Ghrl−/− mice was not due to a basal deficit in
the number of SCs either, as not-injured TA from Ghrl−/−
and WT mice displayed a comparable number of Pax7+
cells (data not shown).
The lack of Ghrl gene negatively impacts SC self-
renewal during muscle regeneration
We have previously demonstrated that UnAG affects SC
biology promoting their activation, stimulating their
Fig. 2 The lack of Ghrl gene
impairs muscle regeneration. a
Representative images (upper
panels) of laminin IF and DAPI
staining of WT and Ghrl−/− TA
muscle sections (scale bar, 100
µm) and quantification of CSA
frequency distribution (lower
panels) of regenerating (i.e.,
centronucleated) myofibers after
7 days from CTX injection. Chi-
square test was used to compare
distributions. Trend P < 0.01.
(CSA mean ± S.E.M. µm2: WT
1254.80 ± 159.64; Ghrl−/−
1055.08 ± 103.78). N= 5 (WT)
and 4 (Ghrl−/−). b Number of
regenerating fibers/mm2 in the
damaged area. Mean ± S.E.M. N
= 5 (WT) and 4 (Ghrl−/−). c
Percentage of fibers with ≥2
central nuclei over the total of
regenerating fibers. Mean ± S.E.
M. N= 5 (WT) and 4 (Ghrl−/−)
132 Endocrine (2018) 62:129–135
proliferation, and enhancing their self-renewal both in vitro
and in vivo [3]. Similarly, Ob induces SC activation in
freeze-injured muscles [4]. To further analyze the effect of
the lack of Ghrl-derived peptides in SC self-renewal, we
administered BrdU to WT and Ghrl−/− mice immediately
after muscle injury and during the following phase of
intense myoblast proliferation, in a system of forced
regeneration consisting in three cycles of CTX injection [3].
Sixty days after the last injury, the number of Pax7+/BrdU
+ SCs, i.e., SCs that cycled at least once and then
underwent self-renewal [3, 22], was significantly reduced in
Ghrl−/− muscle (Fig. 3a,b), demonstrating that pre-
proghrelin deficiency compromises SC self-renewal in vivo.
Noteworthy, the defect in self-renewal did not reflect an
impairment of cell proliferation in Ghrl−/− muscle, as the
number of Pax7+/BrdU+ cells normalized on the total of
BrdU+ cells was further reduced in Ghrl−/− injured muscle
(Fig. 3c), indicating that the lack of preproghrelin specifi-
cally affects SC self-renewal. Fiber CSA distribution ana-
lysis revealed that regenerating muscle from Ghrl−/− mice
Fig. 3 The lack of Ghrl gene impairs SC self-renewal during muscle
regeneration. a Representative images of TA transverse sections
stained with anti-Pax7, anti-BrdU, and DAPI after SC forced
exhaustion procedure, arrow: Pax7+/BrdU+ nucleus (scale bar, 40
μm). b Pax7+/BrdU+ nuclei per mm2. Mean ± S.E.M.; *P < 0.05; N
= 8 (WT) and 8 (Ghrl−/−). c Percentage of Pax7+/BrdU+ nuclei
above the total number of BrdU+ cells. Mean ± S.E.M.; **P < 0.01; N
= 8 (WT) and 8 (Ghrl−/−). d Representative images (upper panels) of
laminin IF and DAPI staining of WT and Ghrl−/− TA muscle sections
(scale bar, 100 µm) after SC forced exhaustion procedure and quan-
tification of CSA frequency distribution of myofibers. Chi-square test
was used to compare distributions. Trend P < 0.05. (CSA mean ± S.E.
M. µm2: WT 2054.35 ± 155.81; Ghrl−/− 1535.93 ± 145.37; P < 0.05).
N= 5 (WT) and 5 (Ghrl−/−)
Endocrine (2018) 62:129–135 133
had significantly smaller fibers compared to WT (Fig. 3d),
indicating that the defect in regeneration persisted at
60 days.
Discussion
In this study, we further extended the comprehension of the
role of Ghrl-derived peptides on skeletal muscle regenera-
tion by using Ghrl−/− mice and demonstrating that deletion
of Ghrl impairs skeletal muscle regeneration. Ghrl codes for
preproghrelin, which, in turn, give rise to different peptides,
AG, UnAG, and Ob. All these peptides have activities on
skeletal muscle; in particular, they promote skeletal muscle
regeneration following CTX- or ischemia-induced damage
[2–6]. The use of preproghrelin-deficient mice allowed us to
demonstrate that muscle regeneration partly depends on
endogenous Ghrl-derived peptides, and that preproghrelin is
involved in the maintenance of the SC pool, by favoring SC
self-renewal. These results are in line with previous data
demonstrating that UnAG and Ob regulate multiple steps of
muscle regeneration by directly acting on SCs, enhancing
their proliferation and self-renewal [3, 4, 6]. Despite the
direct effects of Ghrl-derived peptides on SCs, evidence
that SCs isolated from Ghrl−/− mice differentiate and fuse
exactly as WT SCs (data not shown) indicates the lack of an
autocrine effect of these peptides on SCs.
Moreover, the effects on muscle regeneration as a whole
can also result from the anti-inflammatory activity of Ghrl-
derived peptides [23] on the immune cells that, following
injury, infiltrate the muscle and release several factors that
contribute to muscle repair [24]. Therefore, we can postu-
late that the impairment of regeneration in Ghrl−/− mice
may in part reflect a dysregulated inflammatory response at
the site of damage.
The lack of differences in the number of SCs in basal,
not-injured condition, suggests that Ghrl-derived peptides
might be noncompulsory for the biology of Pax3+ SCs
responsible for the formation of the SC pool during muscle
development. Nevertheless, Ghrl-derived peptides can
affect these SCs, as shown in Tg mice overexpressing Ghrl,
in which the high levels of circulating UnAG increase the
basal number of quiescent SCs in not-injured muscles [3].
The impairment of SC self-renewal observed in Ghrl−/−
mice, on the other hand, suggests that the role of Ghrl-
derived peptides acquires relevance only in adult Pax7+
SCs. This is not totally unexpected, as many intrinsic and
extrinsic factors are peculiar for embryonic and post-natal
muscle formation versus adult muscle regeneration.
By using Ghrl−/− mice, we cannot discern the specific
contribution of each peptide. However, evidence suggests
that AG has a minor role, if any, in muscle regeneration.
Indeed, in ischemia-induced muscle damage, UnAG but not
AG promotes regeneration by enhancing SC expansion [6].
In different systems of muscle wasting, such as denervation-
induced or fasting-induced atrophy, both AG and UnAG act
on skeletal muscle promoting signaling pathways leading to
the maintenance of muscle mass [12]. This anti-atrophic
effect was demonstrated in Ghsr−/− mice, ruling out the
involvement of the canonical AG receptor in muscle
activities elicited by both AG and UnAG. The findings
gathered so far on the muscular effects of AG and UnAG
led to the hypothesis of the existence of a common, yet to be
identified, receptor for AG and UnAG. Data on muscle
regeneration and SCs further suggest that another receptor
—specific for UnAG—might be involved.
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Background: GH deficiency (GHD) is characterized by a cluster of cardiovascular risk factors and
subtle inflammation. We aimed to demonstrate, through a proteomic approach, molecules directly
modulated by GHD and involved in the inflammatory state.
Methods: Ten children with isolated GHD were studied before and after 1 year of treatment with
rhGH and compared with 14 matched controls. A two-dimensional electrophoresis plasma
proteomics analysis was performed at baseline and after GH treatment to identify the top
molecules modulated by GH. In vitro studies on human hepatoma (HepG2) cells were
performed to validate the data.
Results: Twelve of 20 proteomic spots were predicted to be isoforms a and b of haptoglobin (Hp)
and confirmed by liquid chromatography tandem mass spectrometry and Western immunoblot
analyses. Hp levels were higher in patients with GHD than controls at baseline (P, 0.001) and were
reduced following GH treatment (P , 0.01). In HepG2 cells, both GH and IGF-1 were able to
downregulate IL-6–induced Hp secretion. Moreover, Hp secretion was restored in pegvisomant-
treated HepG2 cells.
Conclusions: Hp is a molecule acting in the inflammatory state of GHD and a possible biomarker for GH
treatment. Nevertheless, the contribution of other factors and themolecular pathways involved in theGH
downregulation of Hp remain to be clearly defined. (J Clin Endocrinol Metab 104: 5263–5273, 2019)
GH, beyond its main action on growth, is a pleiotropichormone, with a pivotal metabolic role. It antagonizes
insulin action, stimulates lipolysis, gluconeogenesis, and
glycogenolysis either directly or indirectly by IGF-1 (1–5).
GH deficiency (GHD) is a condition of metabolic
dysregulation, which is coupled to a cluster of cardio-
vascular risk factors (6–8), including central adiposity
(9–12) and insulin resistance (13). Subjects with GHD
exhibit the same metabolic risk factors of patients with
metabolic syndrome (5–15). An increasing number of
studies have indicated that subjects affected by GHD are
more inflamed compared with controls, most likely be-
cause of the immunomodulatory role of GH (9, 16–18). It
is noteworthy that the major part of the studies on the
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2019 Endocrine Society
Received 8 March 2019. Accepted 13 June 2019.
First Published Online 19 June 2019
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raphy tandem mass spectometry; MS, mass spectrometry; MW, molecular weight; O/N,
overnight; pI, isoelectric point; SDS, SD score; T0, at baseline; T12, after 12 months; WIB,
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metabolic and inflammatory role of GH concerns GHD
adults or adolescents, whereas children have been largely
disregarded (19–23). Considering the lack of targets that
characterize the metabolic and inflammatory state in pe-
diatric subjects with GHD, we used a proteomic approach
to identify broad-spectrum changes in plasmatic protein
profile in children affected by isolated GHD. Indeed,
clinical proteomic has acquired increased importance as a
high throughput tool for identification of putative key
proteins in many diseases and target organs, allowing the
comprehension of complex pictures (24–26).
This analysis highlighted differences between pre- and
posttreatment with GH in many plasma proteins. Be-
cause the most considerable identified proteins are acute
phase proteins, in vitro functional studies were per-
formed to further investigate the interplay between
GH/IGF-1 axis and inflammation.
Subjects and Methods
Patients and controls
A total of 10 patients (7 males/3 females) with a mean
age at diagnosis of 11.5 6 2.9 years were enrolled
according to selection criteria: (i) isolated GHD; (ii) no
family history of pituitary dysfunction; (iii) no history of
traumatic brain injury; (iv) prepuberty or starting pu-
berty (Tanner stage 2); (v) naive to rhGH treatment; and
(vi) no chronic treatments with therapies that interfere
with GH or IGF-1 secretion. GHD was diagnosed in the
presence of clinical and auxological criteria, low-normal
IGF-1 levels according to sex and age cutoffs, and im-
paired GH response to two consecutive provocative tests
(27). An impaired response was defined as a peak GH
concentration below 8 mg/L for arginine and clonidine
and below 20 mg/L for GHRH 1 arginine (28). Com-
bined hypopituitarism was excluded in all patients (29).
Fourteen healthy children with normal height, growth
velocity, and IGF-I values, matched for age (mean age,
12.7 6 1.1 years), sex (10 males/4 females), pubertal
status, and body mass index were enrolled as controls.
All children and their parents gave their written informed
consent to participate in this study, which was approved
by the local Ethical Committee of our Hospital (CE
number 14/11).
All subjects with GHD and controls underwent a
complete clinical and auxological evaluation by a trained
research team. Height was measured by the Harpenden
stadiometer and weight with light clothing by using an
electronic scale. Mean height SD score (SDS) for chro-
nological age was calculated according to Tanner na-
tional standards (30). Italian growth charts were used for
height and weight (31).
MRI of the hypothalamopituitary region was ob-
tained in all patients with GHD at the time of diagnosis
(27). In subjects with pituitary anomalies at MRI, genetic
causes of isolated GHD (GH1 and GHRHR mutations)
were excluded.
After a 12-hour overnight fast, morning blood sam-
ples were taken, with patients with GHD undergoing a
further sample for proteomic evaluation at baseline (T0)
and 12 months (T12) after the beginning of rhGH
treatment. Blood samples for confirmation of the pro-
teomic results were also collected from control children.
All biochemical measurements were performed at the
Clinical Laboratory of Novara Hospital. GH and IGF-1
serum levels were measured by Liason hGH e IGF-1
immunoassay (DiaSorin S.p.A., Saluggia, Italy) with a
sensibility of 0.009 to 0.052 ng/mL, and ,3 ng/mL,
respectively.
Serum haptoglobin (Hp; mg/mL) was evaluated by
immunonephelometry, using as reagent the N antisera
antihuman haptoglobin (Siemens Healthcare Diagnos-
tics, Deerfield, IL), with a sensibility of 0.26 to 8.3 g/L,
coefficients of variation intercycle 2.3%, intracycle 3.5%
and total 3.9%. C-reactive protein (CRP) was evaluated
by Siemens Advia Chemistry 1200 (Siemens Healthcare
Diagnostics) with a sensibility of 0.002 to 16.4 mg/dL,
and coefficients of variation intracycle 2.6% and to-
tal 2.7%.
Ferritin was evaluated by chemiluminescence immu-
noassay (ADVIA Centaur XPT; Siemens Healthcare
Diagnostics) with a sensibility of 0.5 to 1650 ng/mL.
Platelets counting and hemoglobin assessment were
performed using Sysmex XN2000 (Sysmex Corporation,
Kobe, Japan) by direct current hydrodynamic focusing
principle and spectrophotometry reading the absorbance
at 555 nm, respectively.
Two-dimensional electrophoresis
Platelet-free plasma samples were obtained by cen-
trifugation at 1300 rpm for 10 minutes at 4°C, followed
by a second centrifugation at 2400 g for 15 minutes at
4°C. Samples were then stored at –80°C until analysis.
Plasma proteins concentration were determined by using
the DC Protein Assay (Bio-Rad, Hercules, CA). For the
first dimension analysis, 50 mg of protein were resus-
pended in a rehydration buffer, according to the method
of de Roos et al. (32) and loaded into the Immobilized pH
Gradient (IPG; 7 cm) 4-7 strip, for an active overnight
(O/N) in-gel rehydration (Bio-Rad). Isoelectric focusing
was performed at 20°Cwith a Protean IEF Cell (Bio-Rad)
using a total of maximum of 8000 V. For the second
dimensional separation, IPG strips were soaked, first in a
reduction equilibration buffer (6M urea, 2% SDS,
0.375M Tris-HCl pH 8.8, 20% glycerol, and 2% w/v
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DTT), followed by an alkylation buffer (6M urea, 2%
SDS, 0.375M Tris-HCl pH 8.8, 20% glycerol, and
2.5% w/v iodoacetamide). The strips were then posi-
tioned in a 10% SDS-Polyacrylamide gels and run at
200 V for 40 minutes. Finally, polyacrylamide gels were
fixed in a solution of 10% methanol and 7% acetic acid
and resolved protein spots visualized with an O/N in-
cubation in Sypro-Ruby fluorescent total protein stain
(Bio-Rad). All samples were evaluated in duplicate.
Image analysis
Fluorescent images of individual IPG 4-7 gels were
captured with a ChemiDoc Imager using a 615- to
645-nM filter (630BP30; BioRad) and analyzed using
PDQuest software (version 8.0) according to the man-
ufacturer’s recommendations. Briefly, the software per-
forms an automated detection and matching of spots
from all gels, calculating individual spot “volumes” by
density/area integration with Sypro-Ruby filtration and
Gaussian modeling. To control for slight differences in
protein loading across gels, the individual spot volumes
were also normalized to the total spot volume for each
gel. For each protein spot, an average value for T0 and
T12 were compared and subjected to Student t test to
determine the spots that were significantly different be-
tween the two time points for each subject. Only those
spots that showed a statistically significant difference
with a P, 0.05 and were consistently replicated between
the cohort of subjects with GHD were chosen for
PDQuest isoelectric point (pI) and molecular weight
(MW) estimations and eventual mass spectrometry (MS)
identification.
MS analysis
Selected spots were cut and digested in-gel with
20 mg/mL trypsin (sequencing grade; Promega, Madison,
WI) at 37°C O/N for liquid chromatography tandem
MS (LC-MS/MS) analysis. The LC-MS/MS analyses
were performed by a micro-LC (Eksigent Technologies,
Dublin, CA) system that included a micro LC200 Eksi-
gent pump with flow module 5 to 50 mL, a pro-
grammable autosampler CTC PAL with a Peltier unit
(1.0 to 45.0°C). The LC system was interfaced with a
56001 TripleTOFTM system (AB Sciex, Concord, Can-
ada) equipped with DuoSprayTM Ion Source and Cal-
ibrant Delivery System. Data were acquired with Analyst
TF 1.7 (AB Sciex). The MS files were searched using
ProteinPilot software, version 4.2 (AB Sciex), with the
Paragon algorithm. Samples were input with the fol-
lowing parameters: cysteine alkylation, digestion by
trypsin, no special factors, and false discovery rate at 1%.
The search was conducted using a through identification
effort of a UniProt Swiss-Prot database containing human
proteins (version 2015.06.09 reviewed, containing 20207
sequence entries).
HepG2 cell culture and treatments
HepG2 (human hepatoma) cells were cultured in
Dulbecco’s Modified Eagle Medium (Sigma-Aldrich,
St. Louis, MO), supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin solution (Sigma-
Aldrich), in a humidified 5% CO2 incubator at 37°C.
Before treatments, cells were cultured O/N in serum-free
medium. HepG2 cells were treated for 24 hours with
20 ng/mL of IL-6 (Sigma-Aldrich) alone or in combi-
nation with 2 mg/mL of rhGH (Genotropin, Pfizer, New
York, NY) or 5 mg/mL of IGF-1 (Increlex, Ipsen,
Boulogne-Billancourt, France). HepG2 cells were also
treated with pegvisomant (25 mg/mL; Pfizer), a specific
GH receptor-inhibitor. After 24 hours of incubation, the
conditioned medium was collected and centrifuged at
1000 g for 10 minutes. Proteins were precipitated with
10% of trichloroacetic acid (Sigma-Aldrich), washed
with cold Acetone (Sigma-Aldrich), resuspended in 6M
Urea (Sigma-Aldrich) and quantified with the Bio-Rad
Protein Assay according to the manufacturer’s instruc-
tions (Bio-Rad).
WIB analysis
Plasma or conditioned medium sample proteins were
size-fractionated under reduction conditions on a 10%
SDS- Polyacrylamide gels and electro-transferred to an
immunoblot polyvinylidene difluoride membrane (Bio-
Rad). Membranes were then blocked for 1 hour in a
solution of Tris-buffered saline - 0.1% Tween-20 con-
taining 5%of nonfat milk and then incubated with 2F4, a
primary antibody against Hp (1:20,000 or 1:5000; Santa
Cruz Biotechnology, Dallas, TX) and detected with a
horseradish peroxidase-conjugated secondary antimouse
IgG (1:5000; Merck Millipore, Darmstadt, Germany).
Immunoreactive proteins were detected using enhanced
chemiluminescence (Pierce Biotechnology Inc, Rockford,
IL) with image capture performed using a CCD-camera
linked to the ChemiDoc (Bio-Rad). Results were quan-
tified using the QuantityOne software with values pre-
sented as arbitrary units.
Amplification and sequencing of the Hp gene: exon
1 and the junction region of Hpdel allele
Genomic DNA was extracted from peripheral blood
of case-subjects and three healthy controls using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions.
The junction region of the Hpdel allele was ampli-
fied by using PCR. In addition, exon 1 of the Hp gene
was coamplified as an amplification control. Primer
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sequences used for the amplification of the junction re-
gion are localized in the exon 5 of the haptoglobin-related
gene (33).





30. PCR reactions were performed with 100 ng of genomic
DNA and 0.18 mL of AmpliTaq Gold Polymerase (Life
Technologies, Foster City, CA), in a total reaction volume of
30 mL. The temperature protocol was: initial denaturation at
95°C for 10minutes followed by 35 cycles with denaturation
at 95°C for 30 seconds, annealing at 60°C for 30 seconds and
an extension at 72°C for 1 minute, with a final extension at
72°C for 10 minutes.
The PCR products were then visualized on a 2%
agarose gel before bidirectional sequencing using the
BigDye Terminator v1.1 Cycle Sequencing Kit and an
ABI PRISM 3130xl automated sequencer (Life Tech-
nologies). Finally, the resulting electropherograms were
aligned with the wild-type human Hp sequence (NM_
005143) using the Multiple Sequence Alignment Clus-
talw software (www.genome.jp/tools/clustalw/).
Statistical analysis
All the data were expressed as mean 6 SD. For
continuous variables, the variation between groups was
calculated by means of Student t test. Statistical signifi-
cance was assumed for P , 0.05. All statistical analyses




At diagnosis, patients showed lower height SDS
(22.236 0.33 vs 0.916 1.02 SDS; P, 0.001) and IGF-
1 SDS (21.50 6 0.11 vs 0.13 6 0.59 SDS; P , 0.001)
compared with controls, whereas no difference was
found in hemoglobin levels (13.56 0.9 mg/dL vs 13.16
0.9 mg/dL). In cases, the GH peak at provocative tests
with GHRH 1 arginine and with arginine/clonidine was
14.3 6 1.7 and 4.3 6 1.1 ng/mL, respectively, and seven
patients had a normal pituitary morphology at MRI,
whereas three showed anterior pituitary hypoplasia.
After 12 months of rhGH treatment, nobody de-
veloped other pituitary deficiencies. The mean rhGH
dose was 7.9 6 2.6 mg/wk (33 6 5 mg/kg/day). Com-
pared with T0, at T12 height SDS (22.23 6 0.33 vs
21.616 0.22 SDS; P, 0.001) and IGF-1 SDS (21.506
0.11 vs 0.12 6 0.53 SDS; P , 0.001) significantly
improved, with a mean growth velocity of 8.3 6 0.7 cm
per year.
Two-dimensional electrophoresis analysis: GHD
pediatric subjects treated with rhGH
At T0 and T12 of rhGH treatment, plasma samples
from each subject were analyzed by two-dimensional-
electrophoresis (2-DE) to evaluate comprehensive changes
in the expression of circulating proteins. By PDQuest
analysis, protein spots significantly altered between T0
and T12 in all subjects with GHD were identified (P ,
0.05). A prediction of the “top 20” spots was made on the
basis of their pI and MW, in combination with the Swiss-
Prot human plasma database and the Tagldent Searches
(http://web.expasy.org) (Table 1). Interestingly, the pro-
tein spot predictions highlighted a predominance of Hp
with 12 of the top 20 spots predicted to be isoforms a and
b of Hp, which showed significantly reduced levels fol-
lowing GH treatment (Fig. 1 and Fig. 2). The predicted
identity ofHpwas confirmed by LC-MS/MS (Table 2) and
by WIB on 2D gels using the specific antibody anti-Hp b.
Confirmation of GH-induced downregulation of Hp
The analysis of the individual data demonstrated the
likely existence of a GH regulation of Hp levels. Indeed,
both the WIB analysis on 2-DE and on plasma samples
using specific anti-Hp b antibody showed a clear re-
duction of Hp levels [Fig. 3(a)–3(b)]. Because it is now
Table 1. Top 20 Plasma Protein Spots With
Expression Significantly Regulated by rhGH in
Subjects With GHD
SSP pIa MW (kDa)a Protein Prediction
202 4.29 42.9 A1AG
306 4.67 52.4 Unknown
604 4 73.9 Unknown
1102 4.84 37.9 Clusterin
1103 4.91 36.5 Clusterin
1104 4.96 46.4 Clusterin
1201 4.97 42 Hp b
1202 5.1 41.4 Hp b
1203 5.21 41.3 Hp b
2102 5.21 40.6 Hp b
3101 5.36 40.8 Hp b
3102 5.38 37.7 Hp b cleaved
3701 5.2 93.7 IGSA
4101 5.5 40.4 Hp b
4102 5.55 38.5 Hp b cleaved
6002 5.68 17.07 Hp a
6103 5.69 40.3 Hp b
6104 5.69 38.2 Hp b cleaved
8001 6.07 16.88 Hp a
9304 6.1 56.1 Unknown
Boldface type highlights predicted Hp isoforms.
Abbreviation: SSP, PDQuest identification.
aPDQuest estimates.
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well demonstrated that CRP levels are negatively regu-
lated by GH in adults (34), to further confirm the GH-
dependent regulation of Hp levels, we used standard
biochemical methods to evaluate both Hp (64.5 6 39.8
vs 3.14 6 5.00 mg/dL, P , 0.001) and CRP levels
(0.124 6 0.174 vs 0.008 6 0.004, P , 0.05) in subjects
with GHD at T0 compared with controls [Fig. 3(c)].
Furthermore, in patients with GHD, Hp (64.5 6 39.8 vs
30.1 6 31.5 mg/dL, P , 0.01) and CRP levels (0.124 6
0.174 vs 0.04 6 0.119 mg/dL, P , 0.05) decreased at
T12 compared with T0 [Fig. 3(d)]. The reduction of Hp
respect to baseline was of 48.0 6 24.4%. We also aimed
to evaluate other acute phase markers and found no
difference in ferritin levels in GHD patients compared
with controls at T0 (25.3 6 8.0 ng/mL vs 28.8 6
10.5 ng/mL) and in GHD subjects at T0 vs T12 (25.3 6
8.0 ng/mL vs 24.76 10.2 ng/mL), whereas platelets were
higher in GHD children than in controls at baseline
(299.56 44.5 103/mL vs 247.86 59.5 103/mL, P, 0.05)
and no difference was found in GHD patients between
T0 and T12 (299.5 6 44.5 103/mL vs 315.9 6 74.5
103/mL; not significant).
Interestingly, we observed that one patient, although
showing modest GH regulation, overall demonstrated
extremely low to undetectable levels of Hp. This subject
showed the presence of only three Hp b isoforms, with
levels at the limit of detection. Despite this result, however,
the data were suggestive of a reduction of all these three
isoforms at T12 at WIB and 2D-E analyses. A preliminary
genetic analysis was performed in this subject to better in-
vestigate this condition of hypohaptoglobinemia. The di-
rect sequencing of the promoter region highlighted the
presence of three single nucleotide polymorphisms in the
heterozygous state (rs5467, rs5469, rs5472) associated
with the Hp deficiency (35, 36).
GH downregulates the expression of Hp in
HepG2 cells
IL-6–treated HepG2 cells are a widely used in vitro
model to study Hp expression (37–39). To confirm the
proteomic results from subjects with GHD, HepG2 cells
were treated with IL-6 in the presence or absence of GH.
The analysis of the conditioned medium demonstrated
that treatment of HepG2 cells with the combination of
IL-6 and GH resulted in a reduction of Hp b secre-
tion compared with HepG2 treated with IL-6 alone
[Fig. 4(a)]. Overall, the secretion of Hp b is in accordance
with our proteomic data, demonstrating a GH-induced
regulation of Hp b secretion. In addition, to validate the
specificity of the GH effect on IL-6–induced increase of
Hp levels, HepG2 cells were treated with pegvisomant, a
GH receptor inhibitor (40, 41) [Fig. 4(b)]. We observed
that, although GH was able to downregulate IL-6–
induced Hp secretion, Hp b secretion was restored in
pegvisomant-treated HepG2 cells.
Effects of IGF-1 on IL-6–induced secretion of Hp
in HepG2 cells
The results obtained by treating HepG2 cells with
pegvisomant demonstrated a direct and specific effect of
rhGH on haptoglobin in an in vitro system, without
Figure 1. 2D-polyacrylamide gel electrophoresis of plasma protein
from patients with GHD. The predicted 12 spots to be hp isoforms
are highlighted by green squares and PDQuest identification
number. IEF, isoelectric focusing; MW, molecular weight.
Figure 2. rhGH treatment in subjects with GHD reduced Hp spot
intensity. A focus and 3D-image of haptoglobin spots at baseline
(T0) and following 12 mos (T12) of rhGH therapy showed a
reduction of the intensities of haptoglobin spots after treatment.
The circled spots are represented in 3D. Subject 1 was
representative of the GHD cohort selected; subject 2 showed a very
low protein expression. 3D, three-dimensional.
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giving information about the possible involvement of
IGF-1. Therefore, to understand if IGF-1 can directly
influence the secretion of Hp induced by IL-6, HepG2
cells were treated with IGF-1 in combination with
20 ng/mL of IL-6. The data demonstrated that also IGF-1
was able to reduce IL-6–induced Hp secretion (Fig. 5).
Discussion
GH is a multitask hormone whose lack, as in GHD, is
responsible for a syndrome ofmetabolic dysregulation. This
condition is accompanied by high cardiovascular risk and a
chronic inflammatory state, because of the presence of
central adiposity, increased visceral fat, insulin resistance,
and dyslipoproteinemia (10, 42). Although there are no
good biomarkers for the assessment of GH therapy, pa-
tients subjected to rhGH substitutive treatment exhibit a
reduction of all risk factors that are associated with the lack
of GH (43). The data here presented identified Hp as
potential biomarker regulated by GH. Indeed, plasmatic
levels of Hp are significantly higher in pediatric patients
with GHD compared with healthy controls, and a sub-
stantial reduction of Hp is visible in GHD subjects after
12 months of rhGH treatment.
Table 2. Hp Identity Confirmation by LC-MS/MS Analysis
SSP 1203












































Trypsin-digested protein spots 1203, 2102 were resolved with LC-MS/MS. The analyzed peptides were identified with UniProt Swiss-Prot database.
Abbreviation: SSP, PDQuest identification.
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Figure 3. WIB and biochemical analysis confirm the Hp downregulation by rhGH in pediatric subjects with GHD. (a) A WIB on a 2D gel was
performed for subjects with GHD (n 5 10) at T0 and T12 using a specific antihaptoglobin b antibody. Two representative subjects are shown.
(b) A representative WIB for Hp b in the plasma of patients with GHD under reduced conditions. (c) Biochemical evaluation of both Hp and CRP
circulating levels in GHD (n 5 10) and control subjects (n 5 14) at T0. *P , 0.05 and **P , 0.01 control subjects vs subjects with GHD. (d)
Biochemical analysis of circulating Hp and CRP in subjects with GHD (n 5 10); the left panel shows the average of all subjects with GHD for
both Hp and CRP before and after rhGH treatment (T0/T12); the right panel shows the downward trend of both circulating proteins level for
each subject. *P , 0.05 T12 vs T0.
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Hp is an abundant acute phase plasma glycoprotein
of the a2-globulin, synthesized predominantly in the
liver. Giving its well-established role as a hemoglobin-
scavenging molecule, Hp protects against toxic effects
associated with intravascular hemolysis-induced hemo-
globin release, facilitating its clearance and preventing
the formation of free radicals mediated by heme iron (44,
45). Acting as an acute phase protein, circulating levels of
Hp increase in response to inflammatory cytokines, such
as IL-6 and IL-1 (46–48). For this reason, Hp is a clinical
marker of the acute-phase response besides being a
routine clinical marker of intravascular hemolysis (49).
The proteomic data presented here on Hp are in-
triguing in view of the pleiotropic effects of GH and on
the chronic inflammation observed in GHD. Indeed,
rhGH supplementation in pediatric subjects with GHD
resulted in a reduction of the plasmatic Hp levels after
12 months of treatment. This result is supported by the
well-known immunomodulatory effect of GH (16–18).
In particular, long-term GH replacement therapy in
adult-onset subjects with GHD modulates inflammatory
activity, reducing IL-6 levels and the synthesis of acute
phase reactants in the liver (43). Because IL-6 is the major
inducing cytokine of Hp, GH-mediated reduction of its
circulating levels supports the results presented here on
Hp, suggesting its use as a possible clinical marker in
pediatric subjects with GHD under GH replacement
therapy. It is interesting to note that the GH effect on Hp
is visible also in a patient with GHD characterized by
extremely low levels of circulating Hp. Genetic analysis
of the promoter region of Hp gene of this patient showed
the presence of three polymorphism (rs5467, rs5469,
rs5472): rs5472 was reported to be significantly asso-
ciated with Hp expression, affecting the serum protein
levels (35), whereas the rs5467 has been demonstrated to
be associated with Hp concentrations (36). Further an-
alyses are needed to confirm the absence of these single
nucleotide polymorphisms in the GHD population
characterized by normal Hp expression.
Although Hp may be a biomarker of GH therapy, it
has to be considered that Hp is a hemoglobin-scavenging
molecule and that it is primarily regulated by an acute
phase inflammation, introducing an important bias
during the follow up of patients. On the other hand, our
results suggest a clear link between GHD and the asso-
ciated inflammatory state, as reported by several epi-
demiological studies (50, 51). Furthermore, in the current
study, we have not found any difference either in baseline
hemoglobin levels between patients and controls or in
other acute phase markers (ferritin and platelets) during
GH treatment, further highlighting the potential role of
Hp. Indeed, the present data increase the knowledge
regarding the role of GH in inflammation and can assist
in the decision to treat patients in which height was
achieved. In contrast to our results, Cruz-Topete et al.
exclude Hp as a possible biomarker of GH replacement
therapy in those with GHD (52). Despite the proteomic
evaluation demonstrating Hp spot intensities to be sig-
nificantly modified with GH treatment, they found no
important differences in the total concentration of Hp by
conventional techniques such as ELISA or WIB. On the
contrary, our data demonstrate substantial differences in
Figure 4. GH directly downregulates Hp secretion in HepG2 cells.
HepG2 cells were treated with IL-6 alone, combined with (a) only
GH or with (b) GH plus PGV in serum-free medium for 24 hours.
The proteins were precipitated from conditioned medium and were
separated by WIB under reduced conditions and analyzed
densitometrically for the secretion of Hp b (n 5 3). $$P , 0.01 vs
control cells; *P , 0.05 vs IL-6–treated cells; #P , 0.05 vs cells
treated with IL-6 and GH combination. PGV, pegvisomant.
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the total Hp concentration byWIB, and these findings are
confirmed by immunonephelometry. These incongru-
ences may be explained by differences in study pop-
ulation because they selected an adult GHD population
with a combined pituitary deficiency in which it is well
known that both a not-complete substitutive treatment or
an overtreatment with glucocorticoids, resulting from the
formulations of therapies, constitute an important con-
founding factor. Given these premises, we investigated
pediatric subjects with an idiopathic and isolated GHD.
Moreover, their investigation was relatively short, with a
follow up of 3 to 4 months. It is well known that the
titration of rhGH treatment is after 6 months, and sta-
bility is more frequently reached after 12 months. In
addition, GH treatment, as demonstrated on bone and
glucose metabolism, frequently has a biphasic effect
with a relatively short acute action completely opposed to
that reported in chronic conditions (53). With this ob-
servation, we believe that Hp might be a possible addi-
tional candidate biomarker of the response to GH
treatment, even if the small size of the population en-
rolled does not allow us to draw definitive conclusions. In
accordance with the incidence of GHD in childhood
(1:4000 to 1:10,000) (54), we were able to select only
10 subjects characterized by a severe GHD condition.
Giving the statistical validity of these preliminary data,
a multicenter longitudinal study is needed to enroll a
greater number of patients and increase knowledge on
the relationship between Hp and GH.
The data presented on HepG2 cells, showing the re-
lationship between GH and Hp, support the result ob-
tained by treating patients with GHD with rhGH,
justifying future clinical studies on a larger number of
patients. Consistent with data already published, HepG2
cells express acute phase proteins in response to IL-6
treatment (38, 39) and, among them, we were able to
observe Hp secretion in a short time after treatment. The
use of pegvisomant, a specific and direct inhibitor of
GHR, demonstrates a direct effect of GH on IL-6–
mediated Hp secretion because treatment with this drug
abolishes the inhibition of Hp production. On the con-
trary, although IGF-1 shows an effect similar to GH on
Hp release, further studies are needed to evaluate the
direct involvement of its receptor in Hp downregulation.
Although a direct inhibitory effect of GH on IL-6–
induced Hp secretion is supported by the present data, the
molecular mechanisms mediating GH actions are still un-
known, and the involvement of different molecular path-
ways may be considered. It is known that GHR belongs to
the superfamily of cytokines receptors. This assumption led
us to speculate on the possibility that GH may bind to the
IL-6 receptor, or vice versa, thus blocking the respective
receptor activation, reducing Hp secretion. Wu et al. (55)
have suggested that SOCS-3 may play an important role in
the suppression of cytokines signaling mediated by GH,
resulting in the downregulation of acute phase response
after injury. It is possible that GH may exert an indirect
action on IL-6, mediated by SOCS-3, which belongs to the
SOCS protein family, whose members inhibit signal
transduction by combining with JAK kinase and competing
for binding with STAT (56, 57). Further studies are needed
to dispel the involvement of these elements in GH action on
IL-6–mediated Hp secretion.
Study limitations
Our study has several potential limitations. It is a pilot
study, and themajor limit is the small size of the population.
For these two reasons, we are not able to investigate the
possible correlations between Hp and clinical (growth
velocity) and biochemical (IGF-1) biomarkers of rhGH
treatment response. Moreover, the molecular mechanisms
beyond our observations remain to be clarified. Future
studies on molecular pathways involved in the GH-
mediated downregulation of Hp and larger longitudinal
studies and randomized trials to evaluate the relationship
between Hp and other markers, used in clinical practice, to
assess the response to rhGH therapy are warranted to
confirm our findings. Finally, a more extensive hormonal
evaluation, including sex hormones, could highlight the
influence of sex and puberty on Hp status.
Conclusions
In the current study, we used a proteomic approach to
analyze the global plasmatic changes between subjects
Figure 5. IGF-1 downregulates Hp secretion in HepG2 cells. HepG2
cells were treated with IL-6 alone or combined with IGF-I in serum-
free medium for 24 hrs. The proteins were precipitated from
conditioned medium and were separated by WIB under reduced
conditions and analyzed densitometrically for the secretion of Hp b.
(n53). $$P , 0.01 vs control cells; **P , 0.01 vs IL-6–treated cells.
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with GHD at baseline conditions and after 12 months of
rhGH treatment, identifying Hp as a possible biomarker
for GH treatment because its total plasma levels decrease
after treatment. By using the in vitro HepG2 hepatocyte
cell model system, we demonstrated the impact that the
GH-IGF-1 axis could have on Hp secretion.
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